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Introduction {#sec005}
============

Despite its low incidence in the general population, pyogenic vertebral osteomyelitis (PVO) remains a challenging disease \[[@pone.0225969.ref001]\]. The management of PVO necessitates a prolonged course of antimicrobial therapy with or without surgical intervention; however, the optimal duration of therapy is unclear and may range from 4 weeks to 3 months \[[@pone.0225969.ref001]\]. The latest guideline released by the Infectious Diseases Society of America (IDSA) suggests a total duration of 6 weeks of parenteral or highly bioavailable oral antimicrobial therapy for most patients with bacterial vertebral osteomyelitis \[[@pone.0225969.ref002]\].

Generally, the treatment duration of PVO depends on the patient's response to therapy, as expressed by clinical symptoms and laboratory data \[[@pone.0225969.ref001]--[@pone.0225969.ref003]\]. In addition to the clinical symptoms, erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) are commonly used to monitor responses to PVO therapy \[[@pone.0225969.ref001], [@pone.0225969.ref002]\]. In a retrospective study, Lin et al proposed that the lowest ESR (≥20 mm/h) and CRP level (≥5 mg/L) during the treatment course could predict osteomyelitis recurrence and suggested using ESR to determine treatment duration \[[@pone.0225969.ref004]\]. However, using a threshold-based approach to predict the clinical course or determine the treatment duration for patients with PVO ignores ESR dynamics throughout the disease course \[[@pone.0225969.ref005]--[@pone.0225969.ref008]\]. In an early study conducted in 1997, Carragee and associates found that patients with an ESR decline (vs pretreatment) of more than 25% after 4-week antibiotic therapy faced a reduced risk of treatment failure \[[@pone.0225969.ref009]\]. Similarly, as mentioned in the IDSA guideline, patients with PVO exhibiting a 50% reduction from the baseline ESR after 4 weeks of antibiotic therapy rarely experience treatment failure \[[@pone.0225969.ref002]\]. Therefore, using an ESR time--value curve (trajectory) may be more appropriate to describe and/or predict the clinical course, duration of treatment, and recurrence for patients with PVO.

By leveraging real-world electronic medical record (EMR) data and tracking national health register--based data, we established a comprehensive set of patient-tracked data for PVO at our institution. We aimed to characterize the ESR trajectories among patients with PVO during the first 6 months of disease. We hypothesized that the initial ESR value and variability in ESR during the first 4 weeks can predict the ESR trajectory pattern of patients with PVO and thus indicate the required treatment duration and likelihood of recurrence of PVO.

Materials and methods {#sec006}
=====================

Study design and study population {#sec007}
---------------------------------

This retrospective study employed a study period from December 2002 to May 2014. All adult patients (≥18 years old) who were admitted to China Medical University Hospital (CMUH) during that time and discharged with a diagnosis of discitis, infective spondylitis, infective spondylodiscitis, or PVO were identified from EMR review, and the diagnoses were further confirmed by infectious disease specialists (CYC and WSC). The inclusion and exclusion criteria and the variable definitions were based on our prior study with some modifications \[[@pone.0225969.ref010]\]. Briefly, patients were excluded if their antibiotics treatment was shorter than 14 days, if they had a non-hematogenous source of vertebral infection (i.e., artificial implants, prior laminectomy within 1 year, spine penetrating trauma, or decubitus ulcer at the same level of vertebral osteomyelitis), if their vertebral osteomyelitis were caused by mycobacterium, fungus, or Brucella species, or if they did not have any image evidence. In the current study, we further excluded patients who had fewer than two ESR measurements within 6 months following the diagnosis of PVO ([Fig 1](#pone.0225969.g001){ref-type="fig"}). In the present study, we linked this PVO cohort with the CMUH clinical research data repository and national death records to obtain biochemistry and mortality data, respectively. This study was approved by the CMUH institutional review board (IRB No: CMUH104-REC2-173 & CMUH105-REC3-068). The corresponding author, CYC, had access to information that could identify individual participants during or after data collection.

![Study population selection process (*N* = 401).\
**Abbreviations:** ESR, erythrocyte sedimentation rate; VO, vertebral osteomyelitis.](pone.0225969.g001){#pone.0225969.g001}

Covariables and outcomes {#sec008}
------------------------

The covariables included the comorbidities of the patients within 1 year prior to or at the time of PVO diagnosis (e.g., diabetes mellitus, intravenous drug users, liver cirrhosis, end stage renal disease, malignancy, other comorbidities, and Charlson's comorbidity index \[CCI\], etc.) \[[@pone.0225969.ref011]\], culture results (i.e., gram-negative pathogens, gram-positive pathogens, polymicrobial microorganisms \[≥ 2 different pathogens\], or no growth), pre-existing or synchronous infections from distant body sites such as lung (pneumonia), urinary tract, intra-abdomen, bloodstream, or skin and soft tissues within 1 month prior to or at the time of PVO diagnosis, timing of surgical intervention, and biochemical profiles. Baseline biochemical profiles of white blood cell (WBC), c-reactive protein (CRP), ESR, blood urea nitrogen (BUN), serum creatinine (SCr), and estimated glomerular filtration rate (eGFR, calculated using chronic kidney disease epidemiology \[CKD-EPI\] collaboration equation) \[[@pone.0225969.ref012]\] were obtained within 7 days (before or after) of PVO diagnosis. The EMRs were reviewed by two Infectious Diseases Specialists (CYC and WSC) to determine patients' delayed operation and recurrence status. We defined surgical procedures performed within 2 weeks after PVO diagnosis as immediate operations. Patients receiving delayed surgery were defined if they met indications for surgical intervention (e.g., neural compression, spinal instability, or presence of epidural or paravertebral abscesses) at the time of PVO diagnosis but were operated (e.g., discectomy, laminectomy) later than 2 weeks after the diagnosis of PVO. Recurrence was defined as any recurrent symptoms and signs (e.g., fever or pain on the affected site accompanied with abnormal image study or increased inflammatory markers, in the absence of other causes) within 6 months after the completion of the initial antibiotic treatment and received another course of antibiotic treatment based on clinician's decision. In-hospital mortality, 3-month mortality, or 6-months mortality following the PVO diagnosis were obtained by linking to the National Death Registry of Taiwan.

Variability quantification of ESR {#sec009}
---------------------------------

The measurement of ESR was performed at the CMUH central laboratory using a Mixrate-X20 ESR automated analyzer (Vital Diagnostics S.r.l., Via Balzella, Forlì, Italy). All ESR values measured within the first 4 weeks following PVO diagnosis were used to estimate the ESR variability (4-week ESR variability). The initial ESR value was the first recorded within the 4 weeks following PVO diagnosis. The variability of ESR was expressed in the following forms: (1) absolute difference (AD) = final ESR value--first ESR value; (2) coefficient of variation (CV, %) = (standard deviation of ESR/mean of ESR) × 100; (3) percent change (PC, %) = (ESR-AD/first ESR value) × 100; and (4) intercept and slope, which were calculated using a multi-level model including both a random intercept and slope with all ESR measurements clustered within the patients.

Group-based trajectory modeling of ESR {#sec010}
--------------------------------------

We used semi-parametric group-based trajectory modeling (GBTM) to characterize the trajectories of ESR values throughout the first 6 months following PVO diagnosis. We used the PROC TRAJs macro function in SAS to fit a semi-parametric mixture model to longitudinal ESR data through the maximum-likelihood method \[[@pone.0225969.ref013]--[@pone.0225969.ref015]\]. GBTM is designed to identify clusters of individuals (ie, trajectory groups) who have followed a similar developmental trajectory for a variable of interest. Such an approach is useful when the number of subgroups and shape of trajectories in the subgroups are unknown. The number of ESR trajectory groups was determined on the basis of their trajectory shape to facilitate meaningful interpretation. Determination of the ESR trajectories was performed before subsequent analysis.

Statistical analysis {#sec011}
--------------------

All statistical analyses were performed using SAS version 9.4 (SAS Institute Inc., Cary, NC, USA) and R version 3.5.1 (R Foundation for Statistical Computing, Vienna, Austria) software. Continuous variables are presented as median and interquartile range (IQR) or mean and standard deviation. Categorical variables are reported as frequency and proportion (%). The associations between ESR trajectory patterns and covariables were analyzed using the Kruskal--Wallis test (nonparametric) or analysis of variance (parametric) for continuous variables and the chi-square test for categorical variables. The test for linear trend from ESR Group 1, 2, to 3 was evaluated by modeling the categorical ESR trajectories as a continuous variable in simple linear regression models. According to the median values of ESR-AD, we dichotomized the study population (patients with ESR-AD \< −9 and those ≥−9 mm/h). To evaluate the association between the first 4-week ESR variability and 6-month ESR trajectory, we included the initial ESR value and ESR-AD (\< −9 vs. ≥−9) as the main predictors and the three ESR trajectory patterns as response variables in an ordinal logistic regression model. The proportional odds assumption of the ordinal logistic regression model was evaluated using a graphical method. Furthermore, variables that were statistically significant in the univariable analysis (polymicrobial culture, DM, ESRD, malignancy, CCI; [Table 1](#pone.0225969.t001){ref-type="table"}) or were clinically relevant (CRP, WBC, eGFR) were included in the multivariable analysis. By incorporating the first-4-week ESR variabilities, initial CRP, and other potential confounders, we built several models using logistic regression to predict prolonged PVO treatment (≥ 12 weeks) and recurrence. In addition, we proposed a directed acyclic graph (DAG) to illustrate the potential causal relationship between the first-4-week ESR variabilities and poor prognosis ([S1 Fig](#pone.0225969.s005){ref-type="supplementary-material"}). The discriminative performance of these serial models was assessed using a receiver operating characteristic curve and *C* statistic. The calibration performance was verified through a calibration plot and the Hosmer−Lemeshow goodness-of-fit test. All analyses were two tailed, and *P* \< 0.05 was considered significant.

10.1371/journal.pone.0225969.t001

###### Baseline demographics and clinical characteristics among patients with pyogenic vertebral osteomyelitis (*N* = 401).

![](pone.0225969.t001){#pone.0225969.t001g}

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variables                                                            ALL\                1\. Initial-Moderate Fast-Response\   2\. Initial-High\    3\. Initial-High\   *P*-value[^a^](#t001fn002){ref-type="table-fn"}   *P*-value for trend[^c^](#t001fn004){ref-type="table-fn"}
                                                                       (N = 401)           (N = 122)                             Fast-Response\       Slow-Response\                                                        
                                                                                                                                 (N = 144)            (N = 135)                                                             
  -------------------------------------------------------------------- ------------------- ------------------------------------- -------------------- ------------------- ------------------------------------------------- -----------------------------------------------------------
  **Age at index date (year)**, median (IQR)                           63.1 (51.6, 71.4)   57.8 (47.3, 70.7)                     63.2 (51.5, 71.3)    65.6 (54.9, 73.4)   0.007                                             0.002

  **Female**, n (%)                                                    138 (34.4)          34 (27.9)                             47 (32.6)            57 (42.2)           0.046                                             0.015

  **Culture**, n (%)                                                                                                                                                                                                        

   Gram-negative pathogen                                              91 (22.7)           28 (23.0)                             34 (23.6)            29 (21.5)           0.022                                             0.013

   Gram-positive pathogen                                              217 (54.1)          64 (52.5)                             81 (56.2)            72 (53.3)                                                             

   Polymicrobial                                                       29 (7.2)            4 (3.3)                               7 (4.9)              18 (13.3)                                                             

   No growth                                                           64 (16.0)           26 (21.3)                             22 (15.3)            16 (11.9)                                                             

  **Comorbidity**, n (%)                                                                                                                                                                                                    

   Diabetes mellitus                                                   145 (36.2)          24 (19.7)                             54 (37.5)            67 (49.6)           \< 0.001                                          \< 0.001

   Intravenous drug users                                              34 (8.5)            15 (12.3)                             13 (9.0)             6 (4.4)             0.075                                             0.024

   Liver cirrhosis                                                     48 (12.0)           15 (12.3)                             15 (10.4)            18 (13.3)           0.748                                             0.781

   End stage renal disease                                             33 (8.2)            3 (2.5)                               14 (9.7)             16 (11.9)           0.017                                             0.007

   Malignancy                                                          35 (8.7)            5 (4.1)                               9 (6.2)              21 (15.6)           0.002                                             0.001

   Myocardial infarction                                               2 (0.5)             1 (0.8)                               \-                   1 (0.7)             0.567                                             0.954

   Congestive heart failure                                            30 (7.5)            7 (5.7)                               8 (5.6)              15 (11.1)           0.144                                             0.095

   Peripheral vascular disease                                         7 (1.7)             1 (0.8)                               5 (3.5)              1 (0.7)             0.142                                             0.914

   Cerebrovascular disease                                             24 (6.0)            5 (4.1)                               8 (5.6)              11 (8.2)            0.379                                             0.169

   Dementia                                                            11 (2.7)            2 (1.6)                               5 (3.5)              4 (3.0)             0.648                                             0.530

   Chronic pulmonary disease                                           21 (5.2)            6 (4.9)                               10 (6.9)             5 (3.7)             0.470                                             0.638

   Connective tissue disease, rheumatologic disease                    3 (0.8)             1 (0.8)                               \-                   2 (1.5)             0.355                                             0.513

   Peptic ulcer disease                                                61 (15.2)           19 (15.6)                             17 (11.8)            25 (18.5)           0.293                                             0.484

   Mild liver disease                                                  46 (11.5)           16 (13.1)                             15 (10.4)            15 (11.1)           0.779                                             0.626

   Hemiplegia or paraplegia                                            6 (1.5)             3 (2.5)                               3 (2.1)              \-                  0.207                                             0.100

   Metastatic solid tumor                                              6 (1.5)             1 (0.8)                               1 (0.7)              4 (3.0)             0.226                                             0.149

   AIDS/HIV                                                            2 (0.5)             1 (0.8)                               1 (0.7)              \-                  0.594                                             0.345

  **Charlson's comorbidity score,**                                                                                                                                                                                         

   Median (IQR)                                                        1.55 ± 2.07         1.09 ± 1.69                           1.47 ± 1.91          2.04 ± 2.43         0.001                                             \< 0.001

   0                                                                   172 (42.9)          60 (49.2)                             66 (45.8)            46 (34.1)           0.005                                             \< 0.001

   1                                                                   81 (20.2)           31 (25.4)                             26 (18.1)            24 (17.8)                                                             

   2                                                                   55 (13.7)           16 (13.1)                             19 (13.2)            20 (14.8)                                                             

   ≥ 3                                                                 93 (23.2)           15 (12.3)                             33 (22.9)            45 (33.3)                                                             

  **Preexisting or synchronous infection**, n (%)                                                                                                                                                                           

   Pneumonia                                                           48 (12.0)           12 (9.8)                              17 (11.8)            19 (14.1)           0.577                                             0.295

   Urinary tract                                                       99 (24.7)           24 (19.7)                             32 (22.2)            43 (31.9)           0.054                                             0.022

   Intra-abdomen                                                       32 (8.0)            6 (4.9)                               14 (9.7)             12 (8.9)            0.316                                             0.253

   Bloodstream                                                         62 (15.5)           13 (10.7)                             22 (15.3)            27 (20.0)           0.117                                             0.038

   Skin and soft tissue                                                24 (6.0)            5 (4.1)                               11 (7.6)             8 (5.9)             0.479                                             0.559

  **Biochemical profiles for diagnosis date ± 7 days**, median (IQR)                                                                                                                                                        

   WBC \* 10^3^, cells/mL                                              10.9 (8.0, 14.4)    9.3 (6.9, 12.9)                       11.8 (8.7, 15.1)     11.5 (8.9, 14.5)    \< 0.001                                          0.002

   WBC \>10,200 cells/mL, n (%)                                        206 (55.7)          50 (43.5)                             78 (61.4)            78 (60.9)           0.007                                             0.007

   CRP, mg/dL                                                          10.9 (4.9, 18.2)    6.1 (3.1, 12.1)                       11.1 (6, 19.6)       15.4 (6.6, 25.0)    \< 0.001                                          \< 0.001

   ESR, mm/hour                                                        81 (61, 100)        62 (44, 75)                           91 (72.5, 104.5)     90 (78, 105)        \< 0.001                                          \< 0.001

   BUN, mg/dL                                                          17 (11, 27)         14.5 (11, 19)                         17 (10, 27)          21 (13, 37.8)       \< 0.001                                          \< 0.001

   SCr, mg/dL                                                          0.9 (0.7, 1.2)      0.8 (0.7, 1)                          0.9 (0.7, 1.2)       1.1 (0.8, 1.8)      \< 0.001                                          \< 0.001

   eGFR, mL/min/1.73 m^2^                                              81.7 (51, 100.8)    91.3 (71.9, 105.4)                    83.5 (57.1, 101.4)   64.3 (34.4, 87.7)   \< 0.001                                          \< 0.001

  **Location of PVO**, n (%)                                                                                                                                                                                                

   Cervical spine                                                      44 (11.0)           17 (13.9)                             15 (10.4)            12 (8.9)            0.419                                             0.199

   Thoracic spine                                                      90 (22.4)           22 (18.0)                             28 (19.4)            40 (29.6)           0.047                                             0.024

   Lumbar spine                                                        290 (72.3)          84 (68.9)                             112 (77.8)           94 (69.6)           0.186                                             0.933

   Sacral spine                                                        68 (17.0)           22 (18.0)                             24 (16.7)            22 (16.3)           0.927                                             0.714

   Multiple vertebral                                                  86 (21.4)           18 (14.8)                             30 (20.8)            38 (28.1)           0.032                                             0.009

  **Abscess**, n (%)                                                                                                                                                                                                        

   Epidural abscess                                                    156 (38.9)          47 (38.5)                             44 (30.6)            65 (48.1)           0.011                                             0.097

   Paraspinal abscess                                                  134 (33.4)          36 (29.5)                             55 (38.2)            43 (31.9)           0.292                                             0.725

   Psoas abscess                                                       88 (21.9)           17 (13.9)                             43 (29.9)            28 (20.7)           0.007                                             0.219

   Any abscess                                                         321 (80.0)          89 (73.0)                             122 (84.7)           110 (81.5)          0.050                                             0.098

   Abscess without drainage or operation                               75 (18.7)           25 (20.5)                             26 (18.1)            24 (17.8)           0.830                                             0.583

  **Treatment**, n (%)                                                                                                                                                                                                      

   Immediate operation                                                 206 (51.4)          64 (52.5)                             74 (51.4)            68 (50.4)           0.946                                             0.738

   Delayed operation                                                   65 (16.2)           9 (7.4)                               27 (18.8)            29 (21.5)           0.005                                             0.002

   Drainage without operation                                          21 (5.2)            8 (6.6)                               6 (4.2)              7 (5.2)             0.683                                             0.638

   Medical treatment alone                                             109 (27.2)          41 (33.6)                             37 (25.7)            31 (23.0)           0.141                                             0.058

  **Total duration of antibiotics therapy**                                                                                                                                                                                 

   Days, mean ± SD[^b^](#t001fn003){ref-type="table-fn"}               105.2 ± 78.2        81.7 ± 54.9                           105.2 ± 66.0         126.4 ± 99.7        \< 0.001                                          \< 0.001

   \<6 weeks                                                           60 (15.0)           24 (19.7)                             21 (14.6)            15 (11.1)           \< 0.001                                          \< 0.001

   6--11 weeks                                                         138 (34.4)          59 (48.3)                             35 (24.3)            44 (32.6)                                                             

   ≥ 12 weeks                                                          203 (50.6)          39 (32.0)                             88 (61.1)            76 (56.3)                                                             

  **Outcomes**, n (%)                                                                                                                                                                                                       

   6-month recurrence                                                  53 (14.1)           9 (7.7)                               20 (15.0)            24 (19.0)           0.037                                             0.011

   In-hospital mortality                                               23 (5.7)            5 (4.1)                               10 (6.9)             8 (5.9)             0.606                                             0.545

   3-month mortality                                                   27 (6.7)            8 (6.6)                               10 (6.9)             9 (6.7)             0.991                                             0.975

   6-month mortality                                                   37 (9.2)            10 (8.2)                              13 (9.0)             14 (10.4)           0.830                                             0.546
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** BUN, blood urea nitrogen; CRP, C-reactive protein; eGFR, estimated glomerular filtration rate; ESR, erythrocyte sedimentation rate; IQR, interquartile range; NA, not applicable; PVO, pyogenic vertebral osteomyelitis; SCr, serum creatinine; SD, standard deviation; WBC, white blood cell count.

^**a**^. *P*-values are calculated by Kruskal-Wallis test for continuous variables and chi-square test for categorical variables.

^**b**^. The treatment duration was significantly different between the first and the second trajectories (Tukey's test p = 0.034) and between the first and the third trajectories (*P* \< 0.001). The difference was not significant between the second and the third trajectories (*P* = 0.055).

^**c**^.*P*-value for trend was calculated by Spearman's correlation test for continuous variables, Cochran-Armitage Trend Test for binary variables, and simple linear regression for variables with more than 3 categories.

Results {#sec012}
=======

Of the 502 patients with a discharge diagnosis of vertebral osteomyelitis, 401 patients met the current inclusion criteria and were included in the final analysis. According to all available ESR measurements of the included patients in the first 6 months following PVO diagnosis, the ESR trajectories were categorized into three distinct groups through GBTM (Figs [1](#pone.0225969.g001){ref-type="fig"} and [2](#pone.0225969.g002){ref-type="fig"}). Group 1 (initially moderate, fast response) comprised 122 patients (30.4%) whose initial ESR values were moderately elevated (\<60 mm/h) before recovering rapidly, Group 2 (initially high, fast response) comprised 144 patients (35.9%) with high initial ESR values (≥60 mm/h) that responded rapidly to treatment, and Group 3 (initially high, slow response) comprised 135 patients (33.7%) with initially high but slowly recovering ESR values ([Fig 2](#pone.0225969.g002){ref-type="fig"}). Contrarily, the trajectories of other inflammatory markers, such as CRP level and white blood cell (WBC) count, did not show distinct patterns with a balanced sample size ([S2 Fig](#pone.0225969.s006){ref-type="supplementary-material"}).

![Group-based trajectory modeling of 6-month erythrocyte sedimentation rate (ESR) among patients with pyogenic vertebral osteomyelitis.](pone.0225969.g002){#pone.0225969.g002}

The patients in Group 3 (median age, 65.6 years) were significantly older than those in Group 1 (57.8 years) and Group 2 (63.2 years) (*P* for trend = 0.002) ([Table 1](#pone.0225969.t001){ref-type="table"}). Compared with Group 1 (27.9%) and Group 2 (32.6%) patients, the patients in Group 3 were more likely to be female (42.2%) (*P* for trend = 0.015). Similarly, with regard to co-morbidities and microbiological data, significantly higher proportions of Group 3 patients had diabetes (49.6%, *P* for trend \< 0.001), end-stage renal disease (11.9%, *P* for trend = 0.007), malignancy (15.6%, *P* for trend = 0.001), and polymicrobial infection (13.3%, *P* for trend = 0.013) than those of the other two groups. The mean Charlson's comorbidity index was 1.09 ± 1.69 for Group 1, 1.47 ± 1.91 for Group 2, and 2.04 ± 2.43 for Group 3, which was significantly different (*P* for trend \< 0.001). Considering the biochemical data, the values of the inflammatory markers (WBCs, CRP, and ESR) at the time of PVO diagnosis were significantly higher for the Group 2 and Group 3 patients (*P* for trend \< 0.001) than those of Group 1. Similarly, patients in Group 2 and Group 3 were more likely to have impaired renal function than those in Group 1 (*P* for trend \< 0.001). Group 3 patients were more likely to have thoracic (29.6%, *P* for trend = 0.024) and multi-site PVO (*P* for trend = 0.009) than those in Group 1 and Group 2 ([Table 1](#pone.0225969.t001){ref-type="table"}).

The reported frequency of abscess formation was lower for Group 1 patients (73%) than for Group 2 and Group 3 patients. Over half of the patients in each group received immediate surgical intervention ([Table 1](#pone.0225969.t001){ref-type="table"}); however, the patients in Group 3 tended to undergo the operation in a more delayed manner (21.5%) than patients in the other two groups (7.4% and 18.8% for Group 1 and Group 2, respectively). Furthermore, the mean duration of antibiotic treatment was significantly longer in Group 3 patients than in Group 1 patients (126.4 vs 81.7 days; Tukey's test *P* \< 0.001) and Group 2 patients (126.4 vs 105.2 days; *P* = 0.055). Compared with the other two groups, significantly more PVO recurrence was observed among Group 3 patients (19.0%, *P* for trend = 0.011). The in-hospital, 3-month, and 6-month mortality rate did not differ significantly among these three patient groups.

The median of the initial ESR value (56 mm/h) of the patients in Group 1 was the lowest among the three groups; however, the medians of the initial ESR (88 mm/h for both groups) were identical for Group 2 and Group 3 patients. The medians of ESR-AD and ESR-PC exhibited an increasing trend from Group 1 (−17 and −33.3%, respectively) to Group 2 (−11 and −13%, respectively) to Group 3 (3.5% and 3.6%, respectively; *P* for trend \< 0.001). Correspondingly, the other variability measure, such as slope, demonstrated a similar increasing pattern from Group 1 to Group 3 patients. The median time intervals from the first ESR value to the last within the first 4 weeks were similar for the three ESR trajectory groups (19.5 to 22 days) ([Table 2](#pone.0225969.t002){ref-type="table"}).

10.1371/journal.pone.0225969.t002

###### Variability of erythrocyte sedimentation rate (ESR) during the first 4 weeks following pyogenic vertebral osteomyelitis diagnosis (*N* = 342), based on ESR trajectory pattern.

![](pone.0225969.t002){#pone.0225969.t002g}

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variables, median (IQR)                                 ALL\                  1\. Initial-Moderate Fast-Decay\   2\. Initial-High\     3\. Initial-High\   *P*-value for trend[^a^](#t002fn002){ref-type="table-fn"}
                                                          (N = 342)             (N = 115)                          Fast-Decay\           Slow-Decay\         
                                                                                                                   (N = 121)             (N = 106)           
  ------------------------------------------------------- --------------------- ---------------------------------- --------------------- ------------------- -----------------------------------------------------------
  Initial ESR value, mm/h                                 78 (55, 95.8)         56 (38.5, 71)                      88 (73, 103)          88 (73.2, 103.8)    \< 0.001

  ESR--AD[^b^](#t002fn003){ref-type="table-fn"}, mm/h     -9 (-27.8, 8)         -17 (-38.5, -1)                    -11 (-29, 8)          3.5 (-13.5, 15.8)   \< 0.001

  ESR--CV[^c^](#t002fn004){ref-type="table-fn"}, %        21.2 (10.7, 35)       30.3 (17.6, 45.5)                  19.4 (9.2, 30.6)      16 (7.1, 26.9)      \< 0.001

  ESR--PC[^d^](#t002fn005){ref-type="table-fn"}, %        -12.7 (-36.4, 11.3)   -33.3 (-53.7, -2.5)                -13.0 (-30.2, 10.9)   3.6 (-12.8, 20.5)   \< 0.001

  Intercept[^e^](#t002fn006){ref-type="table-fn"}, mm/h   79.6 (62.3, 93.4)     61.6 (48.8, 71.1)                  87.9 (73.2, 96.9)     87.5 (72.2, 99.4)   \< 0.001

  Slope[^e^](#t002fn006){ref-type="table-fn"}, mm/h       -0.5 (-0.9, 0)        -0.8 (-1.1, -0.5)                  -0.4 (-0.9, -0.1)     -0.1 (-0.5, 0.3)    \< 0.001

  Days from initial to last measure                       21 (15, 25)           21 (17, 25)                        22 (17, 25)           19.5 (14, 25)       0.151
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** AD, absolute difference; CV, coefficient of variation; ESR, erythrocyte sedimentation rate; IQR, interquartile range; PC, percent change; PVO, pyogenic vertebral osteomyelitis.

^**a**^. *P*-values for trend are calculated by Spearman's correlation.

^**b**^. Absolute difference between the first ESR value and the last within the first 4 weeks following PVO diagnosis.

^**c**^. Coefficient of variation = (Standard deviation/mean) x 100.

^**d**^. Percent change from the first ESR value to the last within the first 4 weeks following PVO diagnosis.

^**e**^. Intercept and slope were calculated using a multilevel model including both a random intercept and slope with all ESR measurements clustered within the patients.

To evaluate the performance of ESR variability in predicting ESR trajectory, we selected the initial ESR value and ESR-AD as main ESR variability measures because these two were readily applicable and are easy to comprehend ([Table 3](#pone.0225969.t003){ref-type="table"}). For each unit increase in initial ESR, the odds of being in ESR trajectory Group 3 compared with the other two trajectory groups were 6% higher (95% confidence interval \[CI\], 5% to 7%). Similarly, this interpretation can be extended to compare the patients of trajectory Groups 2 and 3 with the patients in Group 1 ([Table 3](#pone.0225969.t003){ref-type="table"}, Model 1--1). For patients with an ESR-AD decline of less than 9 mm/h, the odds of being in ESR trajectory Group 3 compared with those of being in either other group were 12.5 times greater (95% CI, 7.4 to 22.0). Correspondingly, the odds for the combined ESR trajectories Group 2 and 3 were 12.5 times greater compared with the odds for trajectory Group 1 ([Table 3](#pone.0225969.t003){ref-type="table"}, Model 1--1). After demographic variables, comorbidities, and baseline eGFR were added in Model 1--2 and polymicrobial infection was added in Model 1--3, the regression coefficients and odds ratios of the initial ESR and ESR-AD changed subtly ([Table 3](#pone.0225969.t003){ref-type="table"}). Based on the initial ESR value and binary ESR-AD, we again plotted the predicted probability of patients with PVO being classified into one of the three ESR trajectory groups ([Fig 3](#pone.0225969.g003){ref-type="fig"}).

10.1371/journal.pone.0225969.t003

###### Prediction of erythrocyte sedimentation rate (ESR) trajectory group (Groups 1, 2, 3) through ordinal logistic regression based on ESR within 4 weeks of pyogenic vertebral osteomyelitis diagnosis.

![](pone.0225969.t003){#pone.0225969.t003g}

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variables                                                  Crude OR\           Model 1--1 (AIC: 583.9) [^b^](#t003fn003){ref-type="table-fn"}   Model 1--2 (AIC: 544.2) [^c^](#t003fn004){ref-type="table-fn"}   Model 1--3 (AIC: 545.5) [^d^](#t003fn005){ref-type="table-fn"}                                  
                                                             (95% CI)                                                                                                                                                                                                                                              
  ---------------------------------------------------------- ------------------- ---------------------------------------------------------------- ---------------------------------------------------------------- ---------------------------------------------------------------- --------------------- -------- ---------------------
  Initial ESR, mm/h                                          1.03 (1.03, 1.04)   0.057                                                            1.06 (1.05, 1.07)                                                0.056                                                            1.06 (1.05, 1.07)     0.056    1.06 (1.05, 1.07)

  ESR--AD ≥ −9 mm/h [^a^](#t003fn002){ref-type="table-fn"}   2.90 (1.94, 4.36)   2.528                                                            12.53 (7.35, 21.96)                                              2.578                                                            13.18 (7.42, 24.17)   2.563    12.98 (7.31, 23.82)

  Age, year                                                  1.02 (1.01, 1.04)                                                                                                                                     0.005                                                            1.01 (0.98, 1.03)     0.006    1.01 (0.98, 1.03)

  Male                                                       0.62 (0.42, 0.91)                                                                                                                                     -0.404                                                           0.67 (0.40, 1.11)     -0.424   0.65 (0.39, 1.09)

  Diabetes mellitus                                          2.63 (1.80, 3.88)                                                                                                                                     0.441                                                            1.55 (0.94, 2.57)     0.427    1.53 (0.93, 2.54)

  ESRD                                                       2.38 (1.25, 4.66)                                                                                                                                     -0.248                                                           0.78 (0.25, 2.38)     -0.330   0.72 (0.23, 2.23)

  Malignancy                                                 3.21 (1.63, 6.56)                                                                                                                                     1.077                                                            2.94 (1.11, 8.15)     1.012    2.75 (1.02, 7.73)

  eGFR, mL/min/1.73 m^2^                                     0.98 (0.98, 0.99)                                                                                                                                     -0.014                                                           0.99 (0.98, 1.00)     -0.014   0.99 (0.98, 1.00)

  CCI ≥ 3                                                    2.42 (1.57, 3.16)                                                                                                                                     -0.287                                                           0.75 (0.38, 1.46)     -0.262   0.77 (0.39, 1.50)

  Polymicrobial infection                                    3.43 (1.63, 7.61)                                                                                                                                                                                                                            0.420    1.52 (0.58, 4.09)
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** AD, absolute difference; AIC, Akaike Information Criterion; CCI, Charlson's comorbidities index; CI, confidence interval; eGFR, estimated glomerular filtration rate; ESR, erythrocyte sedimentation rate; ESRD, end-stage renal disease; OR, odds ratio; PVO, pyogenic vertebral osteomyelitis.

^**a**^. We used the median value of ESR--AD as the cutoff value.

^**b**^. In Model 1--1, initial ESR and ESR--AD were included as predicting variables and three ESR groups as the multilevel response variable.

^**c**^. In Model 1--2, initial ESR, ESR--AD, demographic information (age, gender), baseline comorbidities (diabetes, ESRD, malignancy, and CCI) and baseline eGFR were included as predicting variables and three ESR groups as the multilevel response variable.

^**d**^. In Model 1--3 (full model), initial ESR, ESR--AD, demographic information (age, gender), baseline comorbidities (diabetes, ESRD, malignancy, and CCI), baseline eGFR, and polymicrobial infection were included as predicting variables and three ESR groups as the multilevel response variable.

![Predictive probabilities for erythrocyte sedimentation rate (ESR) trajectories based on the initial ESR value and the absolute difference^a^ in ESR within 4 weeks of pyogenic vertebral osteomyelitis diagnosis.](pone.0225969.g003){#pone.0225969.g003}

Compared with patients with a treatment duration \<12 weeks, those treated ≥12 weeks had significantly higher initial ESR value (median, 71.5 vs 85.5 mm/h) and less ESR variation over the first 4 weeks after PVO diagnosis (median ESR-CV, 25.2% vs 17.6%) ([S1 Table](#pone.0225969.s001){ref-type="supplementary-material"}). Based on the initial ESR and ESR-AD (Model 2--1), the discriminative performance (*C* statistic) for predicting a prolonged treatment (≥12 weeks) was moderate (0.63; 95% CI, 0.57 to 0.69), but it increased to 0.65 (95% CI, 0.59 to 0.71, Model 2--2) after ESR-CV was added to the model. Since the delayed operation and the presence of abscess could influence patients' ESR levels and confound the association between ESR level and outcome ([S2](#pone.0225969.s002){ref-type="supplementary-material"} and [S3](#pone.0225969.s003){ref-type="supplementary-material"} Tables), we included these variables along with the clinical information, such as the comorbidities, delayed surgery, and abscess formation in the full model. The *C* statistic of the full model (Model 2--3) indicated moderate-to-good discrimination (0.75; 95% CI, 0.70 to 0.81) ([Table 4](#pone.0225969.t004){ref-type="table"} and [Fig 4](#pone.0225969.g004){ref-type="fig"}). Furthermore, no 4-week ESR variability measure was significantly associated with the 6-month recurrence of PVO ([S1 Table](#pone.0225969.s001){ref-type="supplementary-material"}). The discriminative performance of the initial ESR and 4-week ESR variability, especially ESR-AD and ESR-CV, in predicting 6-month PVO recurrence was poor (Models 3--1 and 3--2); however, their discriminative performance was improved with the addition of clinical information (Model 3--3; *C* = 0.69; 95% CI, 0.61 to 0.78) ([Table 5](#pone.0225969.t005){ref-type="table"} and [S3 Fig](#pone.0225969.s007){ref-type="supplementary-material"}). The calibration performance of Models 2--3 and 3--3 are illustrated in [S4](#pone.0225969.s008){ref-type="supplementary-material"} and [S5](#pone.0225969.s009){ref-type="supplementary-material"} Figs.

10.1371/journal.pone.0225969.t004

###### Prediction of prolonged treatment duration (≥12 weeks) using logistic regression model based on erythrocyte sedimentation rate within 4 weeks of pyogenic vertebral osteomyelitis diagnosis.

![](pone.0225969.t004){#pone.0225969.t004g}

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variables                                                  Crude OR\           Model 2--1 (AIC: 463.3) [^b^](#t004fn003){ref-type="table-fn"}   Model 2--2 (AIC: 460.1) [^c^](#t004fn004){ref-type="table-fn"}   Model 2--3 (AIC: 373.2) [^d^](#t004fn005){ref-type="table-fn"}                                
                                                             (95% CI)                                                                                                                                                                                                                                            
  ---------------------------------------------------------- ------------------- ---------------------------------------------------------------- ---------------------------------------------------------------- ---------------------------------------------------------------- ------------------- -------- --------------------
  Initial ESR, mm/h                                          1.01 (1.01, 1.02)   0.017                                                            1.02 (1.01, 1.03)                                                0.013                                                            1.01 (1.00, 1.02)   0.014    1.01 (1.00, 1.03)

  ESR--AD ≥ −9 mm/h [^a^](#t004fn002){ref-type="table-fn"}   1.05 (0.69, 1.60)   0.381                                                            1.46 (0.92, 2.34)                                                0.108                                                            1.11 (0.66, 1.88)   -0.122   0.89 (0.46, 1.68)

  ESR--CV                                                    0.98 (0.96, 0.99)                                                                                                                                     -0.017                                                           0.98 (0.97, 1)      -0.020   0.98 (0.96, 1.00)

  Initial CRP, mg/dL                                         1.02 (0.99, 1.04)                                                                                                                                                                                                                          -0.013   0.99 (0.96, 1.02)

  Age, year                                                  1.02 (1.00, 1.03)                                                                                                                                                                                                                          0.019    1.02 (1.00, 1.04)

  Male                                                       0.95 (0.63, 1.44)                                                                                                                                                                                                                          0.455    1.58 (0.90, 2.81)

  Diabetes mellitus                                          1.17 (0.78, 1.76)                                                                                                                                                                                                                          -0.098   0.79 (0.46, 1.35)

  ESRD                                                       0.80 (0.39, 1.63)                                                                                                                                                                                                                          -1.508   0.22 (0.06, 0.79)

  Malignancy                                                 1.73 (0.86, 3.63)                                                                                                                                                                                                                          1.450    4.26 (1.44, 13.91)

  Any abscess                                                1.71 (1.04, 2.83)                                                                                                                                                                                                                          0.672    1.96 (0.97, 4.08)

  Delayed operation                                          1.46 (0.86, 2.52)                                                                                                                                                                                                                          0.524    1.69 (0.79, 3.73)

  eGFR, mL/min/1.73 m^2^                                     0.99 (0.99, 1.00)                                                                                                                                                                                                                          -0.020   0.98 (0.97, 0.99)

  CCI ≥ 3                                                    0.80 (0.50, 1.27)                                                                                                                                                                                                                          -1.061   0.35 (0.16, 0.74)

  ***C* statistic (95% CI)**                                                     **0.63 (0.57--0.69)**                                            **0.65 (0.59--0.71)**                                            **0.75 (0.70--0.81)**                                                                         
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** AD, absolute difference; AIC, Akaike Information Criterion; CCI, Charlson's comorbidities index; CI, confidence interval; CRP, C-reactive protein; CV, coefficient of variation; eGFR, estimated glomerular filtration rate; ESR, erythrocyte sedimentation rate; ESRD, end-stage renal disease; OR, odds ratio; PVO, pyogenic vertebral osteomyelitis.

^**a**^. We used the median value of ESR--AD as the cutoff value.

^**b**^. In Model 2--1, initial ESR, ESR--AD were included as predicting variables and prolonged treatment duration (≥12 weeks) as the dichotomous response variable.

^**c**^. In Model 2--2, initial ESR, ESR--AD, and ESR--CV were included as predicting variables and prolonged treatment duration (≥12 weeks) as the dichotomous response variable.

^**d**^. In Model 2--3 (full model), initial ESR, ESR--AD, ESR--CV, initial CRP, demographic information (age, gender), baseline comorbidities (diabetes, ESRD, malignancy, and CCI), presence of abscess, delayed operation, and baseline eGFR were included as predicting variables and prolonged treatment duration (≥12 weeks) as the dichotomous response variable.

10.1371/journal.pone.0225969.t005

###### Prediction of 6-month recurrence using logistic regression model based on erythrocyte sedimentation rate within 4 weeks of pyogenic vertebral osteomyelitis diagnosis.

![](pone.0225969.t005){#pone.0225969.t005g}

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variables                                                  Crude OR\           Model 3--1 (AIC: 253.3) [^b^](#t005fn003){ref-type="table-fn"}   Model 3--2 (AIC: 253.8) [^c^](#t005fn004){ref-type="table-fn"}   Model 3--3 (AIC: 220.6) [^d^](#t005fn005){ref-type="table-fn"}                                
                                                             (95% CI)                                                                                                                                                                                                                                            
  ---------------------------------------------------------- ------------------- ---------------------------------------------------------------- ---------------------------------------------------------------- ---------------------------------------------------------------- ------------------- -------- -------------------
  Initial ESR, mm/h                                          1.01 (1.00, 1.02)   0.009                                                            1.01 (1.00, 1.02)                                                0.012                                                            1.01 (1, 1.03)      0.007    1.01 (0.99, 1.02)

  ESR--AD ≥ −9 mm/h [^a^](#t005fn002){ref-type="table-fn"}   0.88 (0.46, 1.69)   0.041                                                            1.04 (0.52, 2.08)                                                0.266                                                            1.31 (0.6, 2.89)    0.061    1.06 (0.41, 2.81)

  ESR--CV                                                    1.01 (0.99, 1.02)                                                                                                                                     0.013                                                            1.01 (0.99, 1.03)   0.016    1.02 (0.99, 1.04)

  Initial CRP, mg/dL                                         1.04 (1.00, 1.07)                                                                                                                                                                                                                          0.034    1.04 (0.99, 1.08)

  Age, year                                                  1.00 (0.98, 1.02)                                                                                                                                                                                                                          -0.004   1.00 (0.96, 1.03)

  Male                                                       1.60 (0.85, 3.17)                                                                                                                                                                                                                          0.362    1.44 (0.62, 3.55)

  Diabetes mellitus                                          1.19 (0.64, 2.15)                                                                                                                                                                                                                          -0.080   0.92 (0.40, 2.05)

  ESRD                                                       0.75 (0.17, 2.24)                                                                                                                                                                                                                          -1.986   0.14 (0.01, 1.08)

  Malignancy                                                 1.59 (0.57, 3.87)                                                                                                                                                                                                                          0.638    1.89 (0.48, 6.62)

  Any abscess                                                0.94 (0.47, 2.02)                                                                                                                                                                                                                          0.438    1.55 (0.53, 5.74)

  Delayed operation                                          1.04 (0.45, 2.17)                                                                                                                                                                                                                          -0.278   0.76 (0.21, 2.2)

  eGFR, mL/min/1.73 m^2^                                     1.00 (0.99, 1.01)                                                                                                                                                                                                                          -0.008   0.99 (0.98, 1.01)

  CCI ≥ 3                                                    1.68 (0.86, 3.17)                                                                                                                                                                                                                          0.652    1.92 (0.68, 5.15)

  ***C* statistic (95% CI)**                                                     **0.56 (0.46--0.65)**                                            **0.56 (0.46--0.66)**                                            **0.69 (0.61--0.78)**                                                                         
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** AD, absolute difference; AIC, Akaike Information Criterion; CCI, Charlson's comorbidities index; CI, confidence interval; CRP, C-reactive protein; CV, coefficient of variation; eGFR, estimated glomerular filtration rate; ESR, erythrocyte sedimentation rate; ESRD, end-stage renal disease; OR, odds ratio; PVO, pyogenic vertebral osteomyelitis.

^**a**^. We used the median value of ESR--AD as the cutoff value.

^**b**^. In Model 3--1, initial ESR, ESR--AD were included as predicting variables and 6-month recurrence as the dichotomous response variable.

^**c**^. In Model 3--2, initial ESR, ESR--AD, and ESR--CV were included as predicting variables and 6-month recurrence as the dichotomous response variable.

^**d**^. In Model 3--3 (full model), initial ESR, ESR--AD, ESR--CV, initial CRP, demographic information (age, gender), baseline comorbidities (diabetes, ESRD, malignancy, and CCI), presence of abscess, delayed operation, and baseline eGFR were included as predicting variables and 6-month recurrence as the dichotomous response variable.

![Receiver operating characteristic curve for the predictive model of treatment duration ≥12 weeks.\
**Footnotes:** Predictors in Model 2--1: Initial ESR, ESR − AD ≥ −9. Predictors in Model 2--2: Initial ESR, ESR − AD ≥ −9, ESR − CV. Predictors in Model 2--3: Initial ESR, ESR − AD ≥ −9, ESR − CV, initial CRP, age, gender, diabetes, ESRD, malignancy, CCI ≥ 3, abscess, delayed operation. **Abbreviations:** AD, absolute difference; AUC, area under the ROC curve; CCI, Charlson's comorbidity index; CRP, C-reactive protein; CV, coefficient of variation; ESR, erythrocyte sedimentation rate; ESRD, end-stage renal disease; PVO, pyogenic vertebral osteomyelitis; ROC, receiver operating characteristic curve.](pone.0225969.g004){#pone.0225969.g004}

Discussion {#sec013}
==========

Several findings deserved to be highlighted in the present study. First, we evaluated the trajectories of three inflammatory markers (WBC, CRP, and ESR) among patients with PVO; however, neither the CRP nor WBC trajectories appropriately reflected the clinical course of PVO. A considerable proportion of patients (26%−65%) with osteomyelitis have normal or slightly elevated WBC counts at the time of admission \[[@pone.0225969.ref016]--[@pone.0225969.ref018]\]. Similarly, 44.3% of our patients also had normal initial WBC counts (≤10,200 cells/mL) at the time of PVO diagnosis. Additionally, WBC trajectories did not show significantly different pattern and 73.5% of our study population had flat pattern of WBC (Group 1, [S2B Fig](#pone.0225969.s006){ref-type="supplementary-material"}). From these clinical observations, it is clear that WBC counts are not suitable as a biological maker in follow-up for patients with PVO. Although the roles of both CRP and ESR in the monitoring of the treatment response for osteomyelitis have been extensively evaluated \[[@pone.0225969.ref004], [@pone.0225969.ref009], [@pone.0225969.ref016], [@pone.0225969.ref018]--[@pone.0225969.ref025]\], it remains unclear which is more appropriate for monitoring the clinical course of PVO. With appropriate antibiotic therapy, the inflammatory processes induced by osteomyelitis decrease in intensity progressively. The inflammatory marker CRP may return to its normal level within 1 week \[[@pone.0225969.ref016], [@pone.0225969.ref018], [@pone.0225969.ref026]\]. Such normalization of CRP values, however, may not indicate bacterial eradication but may simply reflect the fact that the inflammatory response to osteomyelitis is too localized or weak to trigger CRP production from hepatocytes \[[@pone.0225969.ref018]\]. In fact, the CRP level for 79.4% of our study population returned to less than 5 mg/dL in the second week after PVO diagnosis (Group 2, [S2A Fig](#pone.0225969.s006){ref-type="supplementary-material"}). Similar clinical observations were reported by Michail and associates, who found that all studied inflammatory markers except ESR returned to a near-normal range after 3 weeks of therapy and suggested that ESR be used to follow-up patients with osteomyelitis \[[@pone.0225969.ref016]\].

Second, through GBTM, we identified three unique ESR trajectory patterns within the first 6 months following PVO diagnosis that were well characterized by clinical features, treatment duration, and recurrence rate among patients with PVO. Few studies have explored the long-term serial ESR changes (ESR trajectory) among patients with osteomyelitis \[[@pone.0225969.ref021], [@pone.0225969.ref022], [@pone.0225969.ref024]\]. Two studies have collapsed the serial ESR information into a single average ESR value over the course of osteomyelitis \[[@pone.0225969.ref022], [@pone.0225969.ref024]\]. Because the therapeutic response may vary throughout the disease course and between individuals, this approach would overlook the inter-patient heterogeneity in treatment response and is unable to characterize the prognostic role of ESR \[[@pone.0225969.ref013]\]. Contrarily, GBTM assumes that the population is composed of distinct groups, each with a different underlying trajectory \[[@pone.0225969.ref027]\]. As demonstrated in our study, the three ESR trajectories represented distinct PVO phenotypes exhibiting significantly different treatment durations and recurrence rates. To the best of our knowledge, it is the first time this approach was used to classify and predict the clinical course of PVO.

Third, the timing of surgical intervention for PVO remains controversial \[[@pone.0225969.ref003]\]. Segreto et al found an immediate operation defined by within 24 hours of admission may reduce complications and mortality among patients with PVO in a claim database \[[@pone.0225969.ref028]\]. Other studies based on single-center experience showed no significant benefit from early abscess drainage \[[@pone.0225969.ref029], [@pone.0225969.ref030]\], which was consistent to our findings. The challenges in tackling the issues related to the timing of surgical intervention, researchers must ensure the timing of PVO diagnosis can be standardized. However, the prerequisite condition is hardly satisfied, if not impossible. Therefore, immediate antibiotics treatment upon the diagnosis of PVO with duration guided by ESR response is still the treatment of choice for PVO. Clinicians should pay attention to the surgical indication, but the timing may be individualized according to patient's response and symptoms.

Fourth, the proposed models are able to predict the longitudinal ESR trajectories and clinical course of PVO. Two studies have suggested that specific values of ESR and CRP during treatment predict osteomyelitis recurrence \[[@pone.0225969.ref004], [@pone.0225969.ref023]\]; however, this prediction may be misleading because of potential reverse causation. By contrast, we proposed to use the initial ESR and the first-4-week ESR variability to predict the clinical course of PVO. Despite the weak predicative performance and moderate-to-good discrimination−*C* statistic ranging from 0.63 (two variables) to 0.75 (full model) for long-term treatment (≥12 weeks) and from 0.56 (two variables) to 0.69 (full model) for recurrence−it is the first evidence that verifies the predictive role of ESR in a real-world setting. From a clinical point of view, the predictive probability graph ([Fig 3](#pone.0225969.g003){ref-type="fig"}) using simple parameters (initial ESR and dichotomous ESR-AD) can help physicians assess earlier whether patients with PVO would have slow response in ESR and necessitate a prolonged antibiotic treatment or have a high likelihood of recurrence. From the *C* statistic results from the simple model to the full model, we realized that clinical information other than ESR also influences the treatment duration and recurrence rate of PVO.

This study has several limitations. First, this was a retrospective study, and the time points and frequencies of ESR measurements following PVO diagnosis were not standardized; variations in these measurements might have affected the ESR trajectory patterns. However, the total number of ESR measurements in this study was 3524, which minimize the confounding by sampling indication. Moreover, the median time intervals of sampling were similar within the first 4 weeks of PVO across the three ESR trajectory groups. Second, we excluded patients who had fewer than two ESR measurements within 6 months following PVO diagnosis. Such exclusion might cause selection bias and influence the ESR trajectory pattern. Only 13 out of 414 cases (3%) were excluded from this study; therefore, the possibility of selection bias was minimal. Third, residual confounding, in particular regarding nutritional status and immune function, was not factored into the proposed models. The dynamics of ESR, however, might serve as an overall summation of all the host--pathogen elements in play. Finally, this study was performed at a single site, and this may limit its generalizability. Nonetheless, from a pathophysiological perspective, our findings can be reliably applied to adult patients with PVO.

In conclusion, the results of this study demonstrate that the PVO population is composed of distinct groups based on ESR trajectory. In addition, the clinical characteristics, treatment duration, and recurrence rate among the patients with PVO are linked with particular ESR trajectory patterns. Using the models proposed in this study and a predictive probability graph, clinicians can predict particular ESR trajectories for patients with PVO and determine which patients require prolonged treatment duration or have a high risk for PVO recurrence. Our findings provide new perspectives within the study of PVO but need to be validated in the future.
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Reviewer \#1: Yes

Reviewer \#2: I Don\'t Know

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: I would suggest minor revions/ clarifications to the manuscript.

\- line 77 highest ESR?

\- What was the rational for considering slow vs. fast decay? Considering the figure 2, what was the explanation for the slope in the group 3 (initial high, slow decay) at week 6, as being coincident with the group 2 (initial high, fast decay)?

\- Clarification of the mixed/synchronous infections. If there are patients with complex infections, as for example concomitant Endocarditis they should be excluded, as it is expected to have higher ESR and persist more than \>4 weeks, which could led to workup bias.

\- Would be interesting more details on the timing of the delayed surgery, at week 2? At recurrence? and include at the discussion. The authors should add a comment on the presence of abscess without surgery - 18-20% in each group, and the impact of ESR.

\- line 309 concluding that the assessment of prolong antimicrobial therapy based on ESR is an extrapolation of data analysis, and gets to the previous point, as further analysis of the delayed or no surgery vs. duration of therapy or recurrence needed.

Reviewer \#2: The authors present a retrospective observational cohort study, which includes a high number of cases of vertebral osteomyelitis (more than 400) from a single center. The study exhaustively analyzes the relationship between the evolution of ESR in the first 4 weeks and the evolution of vertebral osteomyelitis, in terms of duration of antibiotic treatment, recurrence and mortality. They find a relationship between the evolution of ESR levels and the duration of antibiotic therapy and recurrences.

Abstract:

\- The authors define the existence of 3 trajectory pattern (of ESR evolution), but only 1 is described in the abstract (which is the one that has an influence on the increased risk of recurrence. briefly define the 3 trajectory pattern); some brief information should be done of the 3 patterns.

Methods:

\- If there is no space restriction, it would be advisable to explain the study inclusion and exclusion criteria and definitions of the variables; this would be more recommendable In case of space problem, the most important criteria and variables should be briefly explained.

\- One of the most relevant outcomes in this study is recurrence. In a retrospective study like this, the "objective" definition of the outcomes is difficult. However, the recommendation is to use a definition that is as understandable and \"reproducible\" as possible. In this case, \"recurrence\" is defined too imprecisely (e.g., according to this definition, presenting back pain within 6 months after the suspension of antibiotic treatment would be sufficient to diagnose recurrence). Actually, the definition of recurrence seems to be based on the consideration of the responsible (taking into account clinic symptoms and analytics), is that so? But, for instance, were some cases considered recurrence by the attending physician excluded of this outcome due to lack of data supporting this diagnosis?

\- "if a surgical intervention was performed\> 2 weeks after PVO diagnosis, it was defined as a delayed operation" Please, could you explain the meaning of this sentence in more detail?. I guess do you refer to a surgical intervention to treat the infection, although it could also refer to corrective surgery (by sequelae).... If it is a surgical treatment of the infection, does it refer to patients who had an initial indication of surgery, but was it performed "late"? Or who were operated late for lack of initial clinical and / or radiological improvement with antibiotic treatment (but without apparent initial surgical indication? The interpretation of the surgical variable can be very different ("consequence" of bad evolution or "cause" of bad evolution due to the non-early performance)

\- The statistical analysis does not specifically mention the performance of trend analysis, which is after that cited in several sections.

Results:

\- The reference to Figure 1 should be at the end of line 176

\- Figure 2: it is not necessary to repeat the number (1, 2 or 3) on each line

\- Line 193: "P for trend" à the meaning is not explained neither has been previously mentioned the use of this statistics; so, it should be clarified

\- Table 1: the meaning of "NA" is not defined. In some cases there is a result of \"p for trend\" and in others apparently not (that is, in these cases the \"p\" would only reflect that there is some difference between the 3 groups?); this issue should be clarified

\- It would be interesting to know if group 3 had overall more comorbidities (or any comorbidity) compared to the other groups, apart from the specific comorbidities mentioned (lines 192-194)

\- Were there patients with a simultaneous diagnosis of endocarditis? Was this possibility assessed regularly among patients with infection or bacteraemia documented by gram-positive cocci?

\- Could it be analyzed if the indication for immediate surgical treatment changed over time? A percentage of 50% seems very high for current practice

\- The 3 defined trajectory pattern show evident differences in the starting point and evolution of the ESR. However, finally, the prognostic differences seem to be found only between two groups (3 versus 1 + 2 or 1 with respect to 2 + 3 groups). The text and tables 3-5 do not quite clarify this point. In this situation, perhaps after a first descriptive analysis of the 3 groups, the most sophisticated (multivariate) analysis of the outcomes could be done considering the 2 groups that present prognostic differences in the analyzed outcomes; this, in addition, would increase the statistical power to be able to detect differences.

\- In tables 3-5, the different models performed should be explained at the bottom of the table (the tables must be self-explanatory).

\- In the multivariate models described in Tables 3-5, how have been decided which variables to include? It seems somewhat arbitrary \... Have all the variables that could influence the prognosis been considered (particularly those kwown variables increasing the risk of recurrence?

\- I suppose that it has been decided to analyze the ESR because it presents a better predictive profile of the evolution of vertebral osteomyelitis. However, I would like to know what the situation in the case of the ERP and why the analysis of this marker was ruled out. In principle, it is thought that ERP could be the parameter of choice. The evolution of leukocytes, ERP and ESR in a single graph could be of interest; it could also be considered to analyze the mentioned markers according to the current 3 defined trajectory patterns. In supplementary figure 1, it is clear that the division into 3 groups of patients in relation to CPR is not useful; in this sense, surgical treatment should probably have an important role that makes interpretation difficult in these patients (in which CPR should have a significant increase in relation to surgery that distorts the overall results); maybe the ERP analysis could be considered excluding surgery patients or excluding ERP increases related to surgery.

\- Figure 3 is not very intuitive

Discussion

\- Lines 275: "The inflammatory marker CRP returns to its normal level within 1 week". Maybe it means \"may\" (or something similar) returns?

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Author Response

First-4-Week Erythrocyte Sedimentation Rate Variability Predicts Erythrocyte Sedimentation Rate Trajectories and Clinical Course among Patients with Pyogenic Vertebral Osteomyelitis (PONE-D-19-15739)

Review Comments to the Author

Reviewer \#1:

1\. I would suggest minor revions/ clarifications to the manuscript.

Response: Thank you for the comments. We have addressed each of the Reviewers' comments as follows.

Revised contents: None.

2\. line 77 highest ESR?

Response: We have carefully read the study done by Lin et al. (Reference 4 in the revised Text) and confirmed this should be the "lowest" ESR. Lin et al. compared the predictive performance of the different cut-off points (20, 25, 30 mm/hr) for the lowest ESR in predicting recurrence \[1\]. They identified that the cut-off of \>=20 mm/hr for the lowest ESR had the best sensitivity (85%) in predicting recurrence and used that cut-off in their subsequent analysis.

Revised contents: None.

3\. What was the rational for considering slow vs. fast decay? Considering the figure 2, what was the explanation for the slope in the group 3 (initial high, slow decay) at week 6, as being coincident with the group 2 (initial high, fast decay)?

Response: We thank Reviewer 1 for the opportunity to clarify and improve our study.

1\) Using the group-based trajectory statistical modeling (GBTM) on all ESR values measured throughout the first 6 months following PVO diagnosis, we were able to identify three distinct ESR trajectories: Group 1 (initial moderate, fast decay), Group 2 (initial high, fast decay), and Group 3 (initial high, slow decay). In clinical interpretation, slow-decay ESR represents a slow recovery or response of ESR to treatment and fast-decay ESR represents a prompt recovery or response of ESR to treatment. Therefore, we replaced the term "decay" with "response" throughout the manuscript in order to bring more clinical meaning to readers.

2\) We thank Reviewer's observation that Group 3's (initial-high slow-response) mean ESR dropped suddenly at week 6, which coincided with Group 2's mean ESR at week 6. The distribution of ESR for week 5, 6, and 7 are listed in Table R1 below. We confirmed that the actual mean value of ESR for Group 2 and Group 3 indeed decreased dramatically from week 5 to week 6 and the two mean values at week 6 are similar (Group 2 vs 3: 46.59 vs 49.11 mm/hr). This could be well explained by the method we used to model longitudinal trajectories of ESR, a.k.a., Group-Based Trajectory Modeling (GBTM).

Statistically, the unexpected low mean ESR at week 6 for Group 3 is caused by the skewed ESR distribution at week 6. If the distribution of a measure is skewed (i.e., not normally distributed), the mean can be easily affected by the extremely large or extremely small value. For Group 3, at least 25% of patients who had ESR measured at week 6 had an ESR of 11 mm/hr or less and the median was larger than the mean (56 vs 49.11 mm/hr). Therefore, the ESR distribution at week 6 is skewed to the left and median (56 mm/hr) can better represent the overall measure here. Furthermore, GBTM is a specialized application of finite mixture modeling designed to identify clusters of individuals who follow similar trajectories. Therefore, trajectories are what we really focus on, not the change at a single timepoint.

Table R1. ESR distribution at week 5, 6, and 7 following the PVO diagnosis.

　 Week Available N Minimal 25th percentile Median Mean 75th percentile Maximum

Group 1

(N = 122) Week 5 64 3.00 21.75 28.50 30.48 38.00 86.00

Week 6 48 8.00 18.00 24.50 28.77 38.50 67.00

Week 7 44 3.00 14.50 21.00 25.16 33.25 67.00

Group 2

(N = 144) Week 5 75 15.00 51.75 67.00 67.85 83.00 122.00

Week 6 70 10.00 33.25 49.50 46.59 62.75 90.00

Week 7 71 16.00 40.50 57.00 58.61 75.00 113.00

Group 3

(N = 135) Week 5 76 37.00 77.50 91.50 89.61 106.00 129.00

Week 6 70 10.00 11.00 56.00 49.11 82.75 99.00

Week 7 65 15.00 67.00 87.00 85.31 102.00 130.00

Revised content: We replaced the term "decay" with "response" throughout the manuscript.

4\. Clarification of the mixed/synchronous infections. If there are patients with complex infections, as for example concomitant Endocarditis they should be excluded, as it is expected to have higher ESR and persist more than \>4 weeks, which could led to workup bias.

Response:

1\) We thank Reviewer's suggestions that allow us to clarify our study. Mixed and synchronous infections have distinct definitions in our study. Mixed infections are bone infections that were caused by more than one bacterial species. We have also replaced the term "mixed" with "polymicrobial" to improve the clarity. Synchronous infections are the concurrent infections at body sites that are distant from the primary vertebral nidus such as lung (pneumonia), urinary tract, intra-abdomen, bloodstream, or skin and soft tissues. We have added the description for mixed and synchronous infections in MATERIALS and METHODS section.

2\) Of 401 patients in the study population, we identified only 3 patients (0.75%) had infective endocarditis (IE) that met the modified Duke criteria within 30 days prior to the PVO diagnosis and all of them had been treated adequately. In addition, only 1 of these 3 patients were classified in the ESR Group 3 that had high initial ESR and responded slow. Thus, we believe that work-up bias and information bias are unlikely and excluding 3 patients with IE would not change our findings.

Revised content:

1\) Page 6, Line 123: In MATERIALS and METHODS section under Covariables and outcomes, we added definition of mixed infection and synchronous infections as follows: "The covariables included the comorbidities of the patients within 1 year prior to or at the time of PVO diagnosis (e.g., diabetes mellitus, intravenous drug users, liver cirrhosis, end stage renal disease, malignancy, other comorbidities, and Charlson's comorbidity index \[CCI\], etc.), culture results (i.e., gram-negative pathogens, gram-positive pathogens, polymicrobial microorganisms \[≥ 2 different pathogens\], or no growth), pre-existing or synchronous infections from distant body sites such as lung (pneumonia), urinary tract, intra-abdomen, bloodstream, or skin and soft tissues within 1 month prior to or at the time of PVO diagnosis, timing of surgical intervention, and biochemical profiles."

2\) Page 7, Line 127; Page 9, Line 192; Page 11, Line 225; Page 13, Line 271: We replaced the term "mixed infection/culture" with "polymicrobial infection/culture".

3\) Table 1 & Table 3: We replaced the term "mixed" with "polymicrobial".

5\. Would be interesting more details on the timing of the delayed surgery, at week 2? At recurrence? and include at the discussion. The authors should add a comment on the presence of abscess without surgery - 18-20% in each group, and the impact of ESR.

Response:

1\) We thank Reviewer 1's valuable comments. In the present study, two Infectious Disease Specialists (CCY and WSC) had reviewed the medical records for all patients and defined patients receiving delayed surgery if they had initial indications for surgical intervention, such as neural compression, spinal instability, or presence of epidural or paravertebral abscesses, at the time of PVO diagnosis but operated (e.g., discectomy, laminectomy) ≥ 2 weeks after the diagnosis of PVO \[2\].

2\) We agree with Reviewer 1 that the delayed operation and the presence of abscess could influence patients' ESR levels. In Table 1 in the main text, delayed operation was more common in ESR Group 2 (initial-high, fast-response; 18.8%) and Group 3 (initial-high, slow-response; 21.5%), compared with that in Group 1 (initial-moderate, fast-response; 7.4%). In addition, the initial ESR was slightly higher (mean: 80.6 vs 75.8 mm/hr; P = 0.196) and the absolute decrease in ESR within the first 4 weeks was less (mean: -4.4 vs -9.3 mm/hr; P = 0.269) in patients receiving delayed operations than in patients receiving immediate operations (Table R2). Furthermore, 86.2% of patients with delayed operations were classified as ESR Group 2 or Group 3, compared with 68.9% of patients with immediate operations. Thus, patients with delayed operations tended to have high initial ESR and slowly responded ESR level, compared with those with immediate operations. However, the treatment duration (delayed vs immediate operation, 118 vs 100 days; P = 0.097) and the 6-month recurrence (14.5% vs 15.8%; P =0.810) were similar.

 

Table R2. The 4-week ESR variability and 6-month ESR trajectory by the surgical treatment.

Immediate operation

(N = 206) Delayed operation

(N = 65) Drainage without operation

(N = 21) No operation

(N = 109) p-value

ESR variability within 4 weeks of PVO diagnosis, mean ± SD

Initial ESR 75.8 ± 29.5 b 80.6 ± 26.8 b 67.4 ± 18.3 74.5 ± 27.2 0.587

ESR-AD -9.3 ± 29.9 c -4.4 ± 30.9 c -14.1 ± 33.4 -11.6 ± 25.9 0.489

ESR-CV 26.1 ± 18.1 20.8 ± 14.1 27.6 ± 20.9 23.2 ± 18.0 0.254

ESR-PC 9.5 ± 202.6 3.7 ± 49.2 -13.0 ± 48.1 -9.6 ± 49.0 0.315

ESR-intercept 76.3 ± 21.1 83.5 ± 20.3 69.8 ± 12.1 77.4 ± 20.3 0.845

ESR-Slope -0.4 ± 0.7 -0.4 ± 0.7 -0.7 ± 0.9 -0.5 ± 0.6 0.220

ESR trajectory within 6 months of PVO diagnosis a, n (%) 0.054

Group 1 64 (31.1) 9 (13.9) 8 (38.1) 41 (37.6)

Group 2 74 (35.9) 27 (41.5) 6 (28.6) 37 (33.9)

Group 3 68 (33.0) 29 (44.6) 7 (33.3) 31 (28.5)

Treatment duration, day, mean ± SD 100.4 ± 77.0 d 118.4 ± 89.8 d 80.2 ± 51.9 111.2 ± 76.4 0.375

Recurrence, n (%) 30 (15.8) e 9 (14.5) e 5 (25.0) 9 (8.7) 0.149

Abbreviations: AD, absolute difference; CV, coefficient of variation; ESR, erythrocyte sedimentation rate; PC, percent change; PVO, pyogenic vertebral osteomyelitis; SD, standard deviation.

a\. Group 1: initial-moderate, fast-response; Group 2: initial-high, fast-response; Group 3: initial-high, slow-response.

b\. The initial ESR for patients with immediate operation and those with delayed operation was not significantly different (P = 0.196).

c\. The ESR-AD for patients with immediate operation and those with delayed operation was not significantly different (P = 0.269).

d\. The treatment duration for patients with immediate operation and those with delayed operation was not significantly different (P = 0.097).

e\. The recurrence status for patients with immediate operation and those with delayed operation was not significantly different (P = 0.810).

3\) As shown in Table 1 in the main text, the presence of abscess without drainage/operation was comparable across the three ESR trajectory groups (Group 1: 20.5%; Group 2: 18.1%; Group 3: 17.8%). The initial ESR was slightly lower for patients without abscess than those with abscess (no abscess: 70.5; abscess without drain: 77.3; abscess with drain: 76.8 mm/hr; Table R3), but was comparable between abscess with and without drainage/operation (P = 0.918). The proportion of PVO patients receiving abscess drainage that was classified into ESR Group 2 or Group 3 were also comparable (Table R3). Thus, patients with abscess tended to have higher initial ESR and slowly responded ESR level, but having drainage/operation or not did not affect their ESR patterns. However, among patients with PVO accompanied with paraspinal abscesses, drainage itself did not alter the disease course in the regard of treatment duration (no drainage vs drainage, 116 vs 103 days; P = 0.077) or the 6-month recurrence (6.8% vs 16.2%; P = 0.044).

Table R3. The 4-week ESR variability and 6-month ESR trajectory by the presence of abscess.

Variables No abscess

(N = 80) Abscess without drainage/ operation

(N = 75) Abscess

with

drainage/ operation

(N = 246) p-value

ESR variability within 4 weeks of PVO diagnosis, mean ± SD

Initial ESR 70.5 ± 29.2 77.3 ± 26.2 b 76.8 ± 28.3 b 0.181

ESR-AD -11.1 ± 30.5 -11.4 ± 25.0 -8.3 ± 30.1 0.418

ESR-CV 25.3 ± 14.8 22.5 ± 19.1 25.1 ± 18.1 0.810

ESR-PC -5.9 ± 55.4 -9.7 ± 49.1 8.9 ± 189.9 0.407

ESR-intercept 73.9 ± 20.4 79.8 ± 19.9 77.5 ± 20.8 0.382

ESR-Slope -0.5 ± 0.7 -0.5 ± 0.6 -0.4 ± 0.7 0.199

ESR trajectory within 6 months of PVO diagnosis a, n (%) 0.114

Group 1 33 (41.2) 25 (33.3) 64 (26.0)

Group 2 22 (27.5) 26 (34.7) 96 (39.0)

Group 3 25 (31.2) 24 (32.0) 86 (35.0)

Treatment duration, day, mean ± SD 100.1 ± 92.7 116.3 ± 72.4 c 103.5 ± 74.8 c 0.986

Recurrence, n (%) 11 (14.7) 5 (6.8) d 37 (16.2) d 0.133

Abbreviations: AD, absolute difference; CV, coefficient of variation; ESR, erythrocyte sedimentation rate; PC, percent change; PVO, pyogenic vertebral osteomyelitis; SD, standard deviation.

a\. Group 1: initial-moderate, fast-response; Group 2: initial-high, fast-response; Group 3: initial-high, slow-response.

b\. The initial ESR for patients who had abscess without drainage and those who had abscess with drainage was not significantly different (P = 0.918).

c\. The treatment duration for patients who had abscess without drainage and those who had abscess with drainage was not significantly different (P = 0.077).

d\. The recurrence status for patients who had abscess without drainage and those who had abscess with drainage was significantly different (P = 0.04).

In our original multivariable analyses, we have adjusted for delayed operation and the presence of abscess in the analysis for prolonged treatment duration (Table 4 in the main text) and recurrence (Table 5 in the main text). Neither delayed operation (adjusted OR, 1.49; 95% CI, 0.71 -- 3.22) nor the presence of abscess (adjusted OR, 1.97; 95% CI, 0.98 -- 4.04) was significantly associated with prolonged treatment. Similarly, no significant association between delayed operation or abscess with recurrence was observed.

Therefore, we have included delayed operation, presence of abscess, and ESR variability measures (initial ESR, ESR-AD, and ESR-CV) in the fully adjusted model, which have adjusted for the potential confounding induced by delayed operation and presence of abscess on outcomes.

Revised content:

1\) Page 14, Line 283: In RESULTS section, we added the following: "Since the delayed operation and the presence of abscess could influence patients' ESR levels and confound the association between ESR level and outcome (Supplementary Table 2 and 3), we included these variables along with the clinical information, such as the comorbidities, delayed surgery, and abscess formation in the full model."

2\) Page 16, Line 339: In DISCUSSION section, we added the third discussion point: "Third, the timing of surgical intervention for PVO remains controversial \[3\]. Segreto et al found an immediate operation defined by within 24 hours of admission may reduce complications and mortality among patients with PVO in a claim database \[4\]. Other studies based on single-center experience showed no significant benefit from early abscess drainage \[5, 6\], which was consistent to our findings. The challenges in tackling the issues related to the timing of surgical intervention, researchers must ensure the timing of PVO diagnosis can be standardized. However, the prerequisite condition is hardly satisfied, if not impossible. Therefore, immediate antibiotics treatment upon the diagnosis of PVO with duration guided by ESR response is still the treatment of choice for PVO. Clinicians should pay attention to the surgical indication, but the timing may be individualized according to patient's response and symptoms."

3\) Supplementary: We added Supplementary Table 2 and Table 3 to show the ESR variability and ESR trajectory grouping by the surgical treatment or by the presence of abscess.

6\. Line 309 concluding that the assessment of prolong antimicrobial therapy based on ESR is an extrapolation of data analysis, and gets to the previous point, as further analysis of the delayed or no surgery vs. duration of therapy or recurrence needed.

Response:

We thank Reviewer 1's suggestion. We agree that delayed operation could influence the ESR pattern and contribute to the prolonged treatment duration or recurrence (aka: an important confounding factor). However, the predictive probability estimated based on a practical model is not an extrapolation, but a practical conversion from statistical modeling into clinical use. We have examined the 4-week ESR variability and the 6-month ESR trajectory by the operation timing (i.e., immediate operation, delayed operation, drainage only, no operation) in Table R2. Patients with delayed operations tended to have high initial ESR and slowly responded ESR level, compared with those with immediate operations. However, the treatment duration and the 6-month recurrence were not significantly different (Table R2). Please also see our response to the comment \#5 for more details.

Revised content:

1\) Page 14, Line 283: In RESULTS section, we added the following: "Since the delayed operation and the presence of abscess could impact patients' ESR levels and confound the association between ESR level and outcome (Supplementary Table 2 and 3), we included these variables along with the clinical information, such as the comorbidities, delayed surgery, and abscess formation in the full model."

2\) Page 16, Line 339: In DISCUSSION section, we added the third discussion point: "Third, the timing of surgical intervention for PVO remains controversial \[3\]. Segreto et al found an immediate operation defined by within 24 hours of admission may reduce complications and mortality among patients with PVO in a claim database \[4\]. Other studies based on single-center experience showed no significant benefit from early abscess drainage \[5, 6\], which was consistent to our findings. The challenges in tackling the issues related to the timing of surgical intervention, researchers must ensure the timing of PVO diagnosis can be standardized. However, the prerequisite condition is hardly satisfied, if not impossible. Therefore, immediate antibiotics treatment upon the diagnosis of PVO with duration guided by ESR response is still the treatment of choice for PVO. Clinicians should pay attention to the surgical indication, but the timing may be individualized according to patient's response and symptoms."

3\) Page 17, Line 361: We modified the following sentence: "From a clinical point of view, the predictive probability graph (Figure 3) using simple parameters (initial ESR and dichotomous ESR-AD) can help physicians assess earlier whether patients with PVO would have slow response in ESR and necessitate a prolonged antibiotic treatment or have a high likelihood of recurrence."

4\) Supplementary: We added Supplementary Table 2 and Table 3 to show the ESR variability and ESR trajectory grouping by the surgical treatment or by the presence of abscess.

 

Reviewer \#2:

1\. The authors present a retrospective observational cohort study, which includes a high number of cases of vertebral osteomyelitis (more than 400) from a single center. The study exhaustively analyzes the relationship between the evolution of ESR in the first 4 weeks and the evolution of vertebral osteomyelitis, in terms of duration of antibiotic treatment, recurrence and mortality. They find a relationship between the evolution of ESR levels and the duration of antibiotic therapy and recurrences.

Response: We are very grateful for the reviewer's positive comments/suggestions and for the insightful reviews. Below we describe our responses point-by-point to each comment given in italics. In the revised manuscript, changes to the text are noted with red text.

Revised content: None.

Abstract:

2\. The authors define the existence of 3 trajectory pattern (of ESR evolution), but only 1 is described in the abstract (which is the one that has an influence on the increased risk of recurrence. Briefly define the 3 trajectory pattern); some brief information should be done of the 3 patterns.

Response: Thank you. We have added a brief description of the 3 trajectory patterns in the abstract.

Revised content:

Page 2, Line 50: In ABSTRACT section under Results, we added: "Three ESR trajectory patterns were identified though GBTM among patients with PVO: Group 1, initial moderate high ESR with fast response; Group 2, initial high ESR with fast response; Group 3, initial high ESR with slow response."

 

Methods:

3\. If there is no space restriction, it would be advisable to explain the study inclusion and exclusion criteria and definitions of the variables; this would be more recommendable In case of space problem, the most important criteria and variables should be briefly explained.

Response: We thank Reviewer 2's valuable suggestions. We previously did not give much details about the inclusion/exclusion criteria because our study population has been described in our prior published work \[2\] However, we agree with Reviewer 2 that it would be better comprehensible if we provide more details. Therefore, we have expanded the METHODS section to elaborate the inclusion/exclusion criteria and the definition of important variables in our study.

Revised content:

1\) Page 6, Line 107: In MATERIALS and METHODS section under Study design and study population, we added the inclusion and exclusion criteria of the study population as follows: "Briefly, patients were excluded if their antibiotics treatment was shorter than 14 days, if they had a non-hematogenous source of vertebral infection (i.e., artificial implants, prior laminectomy within 1 year, spine penetrating trauma, or decubitus ulcer at the same level of vertebral osteomyelitis), if their vertebral osteomyelitis were caused by mycobacterium, fungus, or Brucella species, or if they did not have any image evidence. In the current study, we further excluded patients who had fewer than two ESR measurements within 6 months following the diagnosis of PVO."

2\) Page 6, Line 123: In MATERIALS and METHODS section under Covariates and outcomes, we re-wrote as follows: "The covariables included the comorbidities of the patients within 1 year prior to or at the time of PVO diagnosis (e.g., diabetes mellitus, intravenous drug users, liver cirrhosis, end stage renal disease, malignancy, other comorbidities, and Charlson's comorbidity index \[CCI\], etc.), culture results (i.e., gram-negative pathogens, gram-positive pathogens, polymicrobial microorganisms \[≥ 2 different pathogens\], or no growth), pre-existing or synchronous infections from distant body sites such as lung (pneumonia), urinary tract, intra-abdomen, bloodstream, or skin and soft tissues within 1 month prior to or at the time of PVO diagnosis, timing of surgical intervention, and biochemical profiles. Baseline biochemical profiles of white blood cell (WBC), c-reactive protein (CRP), ESR, blood urea nitrogen (BUN), serum creatinine (SCr), and estimated glomerular filtration rate (eGFR, calculated using chronic kidney disease epidemiology \[CKD-EPI\] collaboration equation) were obtained within 7 days (before or after) of PVO diagnosis. We defined surgical procedures performed within 2 weeks after PVO diagnosis as immediate operations and those performed later than that as delayed operations. Prolonged antibiotic treatment duration was defined as treatment duration longer than or equals to 12 weeks. The EMRs were reviewed by two Infectious Diseases Specialists (CYC and WSC) to determine patients' delayed operation and recurrence status. We defined surgical procedures performed within 2 weeks after PVO diagnosis as immediate operations. Patients receiving delayed surgery were defined if they had initial indications for surgical intervention (e.g., neural compression, spinal instability, or presence of epidural or paravertebral abscesses) at the time of PVO diagnosis but were operated (e.g., discectomy, laminectomy) later than 2 weeks after the diagnosis of PVO. Recurrence was defined as any recurrent symptoms and signs (e.g., fever or pain on the affected site accompanied with abnormal image study or increased inflammatory markers, in the absence of other causes) within 6 months after the completion of the initial antibiotic treatment and received another course of antibiotic treatment based on clinician's decision. In-hospital mortality, 3-month mortality, or 6-month mortality following the PVO diagnosis were obtained by linking to the National Death Registry of Taiwan."

4\. One of the most relevant outcomes in this study is recurrence. In a retrospective study like this, the "objective" definition of the outcomes is difficult. However, the recommendation is to use a definition that is as understandable and \"reproducible\" as possible. In this case, \"recurrence\" is defined too imprecisely (e.g., according to this definition, presenting back pain within 6 months after the suspension of antibiotic treatment would be sufficient to diagnose recurrence). Actually, the definition of recurrence seems to be based on the consideration of the responsible (taking into account clinic symptoms and analytics), is that so? But, for instance, were some cases considered recurrence by the attending physician excluded of this outcome due to lack of data supporting this diagnosis?

Response: We thank Reviewer 2 for the opportunity that allows us to clarify the definition of recurrence. The medical records were reviewed by two infectious specialists (CYC and WSC) to determine patients' recurrence status. Recurrence was defined as having any recurrent symptoms or signs (e.g., fever, pain on the affected site, or abnormal inflammatory markers in the absence of other causes) within 6 months after the completion of the initial antibiotic treatment and received another course of antibiotic treatment based on clinician's decision. In the clinical care for the patients with PVO after the treatment completion, clinicians often follow patients for treatment response by examining their inflammatory markers levels or MRI image study. Patients having back pain within 6 months after treatment completion would not be considered as having recurrence if they do not have clinical evidence such as increased informatory markers or abnormal image data to support.

In our study, 48 of 53 (90.6%) patients with recurrence and 202 of 323 (62.5%) patients without recurrence had their ESR measured after the treatment completion and the days from the end of treatment to the closest ESR was comparable between two groups (median, 13 days; Table R4). The ESR value was significantly higher among patients having 6-month recurrence than that among patients without recurrence (median, 47 vs 22 mm/hr, P \< 0.001), supporting the accuracy of recurrence status.

Table R4. The ESR value after treatment completion for patients with PVO, by status of 6-month recurrence.

Variables, median (IQR) No Recurrence

(N = 323) Recurrence

(N = 53) p-value

Available N 202 (62.5%) 48 (90.6%)

ESR (mm/hr) 22.0 (11.0-47.3) 47.0 (25.0-86.0) \< 0.001

Days from the end of antibiotic

treatment to the closest ESR 13.0 (3.0-26.8) 13.0 (6.0-31.8) 0.397

Revised content:

Page 7, Line 135: In the MATERIALS and METHODS section under Covariables and outcomes, we added the following sentences to clarify the definition of recurrence: "The EMRs were reviewed by two Infectious Diseases Specialists (CYC and WSC) to determine patients' delayed operation and recurrence status. .... Recurrence was defined as any recurrent symptoms and signs (e.g., fever or pain on the affected site accompanied with abnormal image study or increased inflammatory markers, in the absence of other causes) within 6 months after the completion of the initial antibiotic treatment and received another course of antibiotic treatment based on clinician's decision."

5\. "if a surgical intervention was performed\> 2 weeks after PVO diagnosis, it was defined as a delayed operation" Please, could you explain the meaning of this sentence in more detail?. I guess do you refer to a surgical intervention to treat the infection, although it could also refer to corrective surgery (by sequelae).... If it is a surgical treatment of the infection, does it refer to patients who had an initial indication of surgery, but was it performed "late"? Or who were operated late for lack of initial clinical and / or radiological improvement with antibiotic treatment (but without apparent initial surgical indication? The interpretation of the surgical variable can be very different ("consequence" of bad evolution or "cause" of bad evolution due to the non-early performance)

Response:

In the present study, two Infectious Disease Specialists (CCY and WSC) had reviewed the medical records for all patients and defined patients receiving delayed surgery if they had initial indications for surgical intervention (e.g., neural compression, spinal instability, or presence of epidural or paravertebral abscesses) at the time of PVO diagnosis but were operated (e.g., discectomy, laminectomy) later than 2 weeks after the diagnosis of PVO. Therefore, the delayed surgery was not the consequence of worse ESR response or insufficient treatment.

Revised content:

Page 7, Line 135: In the MATERIALS and METHODS section under Covariables and outcomes, we edited the following sentences: "The EMRs were reviewed by two Infectious Diseases Specialists (CYC and WSC) to determine patients' delayed operation and recurrence status. We defined surgical procedures performed within 2 weeks after PVO diagnosis as immediate operations. Patients receiving delayed surgery were defined if they had initial indications for surgical intervention (e.g., neural compression, spinal instability, or presence of epidural or paravertebral abscesses) at the time of PVO diagnosis but were operated (e.g., discectomy, laminectomy) later than 2 weeks after the diagnosis of PVO."

6\. The statistical analysis does not specifically mention the performance of trend analysis, which is after that cited in several sections.

Response: We thank Reviewer for pointing out this issue. The test for linear trend from ESR Group 1, 2, to 3 was evaluated by modeling the categorical ESR trajectories as a continuous variable in simple linear regression models. We have added a few sentences in the METHOD section to clarify the trend analysis.

Revised content:

Page 9, Line 183: In MATERIALS and METHODS section under Statistical analysis, we added the following sentence: "The test for linear trend from ESR Group 1, 2, to 3 was evaluated by modeling the categorical ESR trajectories as a continuous variable in simple linear regression models."

Results:

7\. The reference to Figure 1 should be at the end of line 176

Response: We have edited the manuscript according to the Reviewer 2's suggestion.

Revised content:

Page 11, Line 205: In RESULTS section, we moved the Figure 1 reference to the end of the first sentence: "Of the 502 patients with a discharge diagnosis of vertebral osteomyelitis, 401 patients met the current inclusion criteria and were included in the final analysis (Figure 1)."

8\. Figure 2: it is not necessary to repeat the number (1, 2 or 3) on each line

Response: Thank you. We have modified the Figure 2 accordingly.

Revised content: In Figure 2, we've replaced the numbers (1, 2, 3) with circles, triangles, and squares.

9\. Line 193: "P for trend" à the meaning is not explained neither has been previously mentioned the use of this statistics; so, it should be clarified

Response: Thank you. In Table 1, we have added an additional column for "p value for trend", which was derived from the test for linear trend by modeling the categorical ESR trajectories as a continuous variable in simple linear regression models.

Revised content:

Page 9, Line 183: In MATERIALS and METHODS under Statistical analysis, we have added detailed information of trend analysis: "The test for linear trend was evaluated by modeling the categorical ESR trajectories as a continuous variable in simple linear regression models."

10\. Table 1: the meaning of "NA" is not defined. In some cases there is a result of \"p for trend\" and in others apparently not (that is, in these cases the \"p\" would only reflect that there is some difference between the 3 groups?); this issue should be clarified

Response: Thank you. In Table 1, we have added an additional column for "p value for trend" and remove the "NA".

Revised content: Revised Table 1.

11\. It would be interesting to know if group 3 had overall more comorbidities (or any comorbidity) compared to the other groups, apart from the specific comorbidities mentioned (lines 192-194)

Response: Thank you. We have provided additional comorbidities based on Charlson's comorbidity \[7\] and also the Charlson's comorbidity index (CCI) in Table 1 and have added one sentence in the RESULTS section. The original comorbidities we presented (diabetes, IV drug use, ESRD, and malignancy) were significantly associated with ESR trajectory groups and no additional comorbidity was significant (Table 1). The mean CCI was 1.09 ± 1.69 for ESR group 1, 1.47 ± 1.91 for ESR group 2, and 2.04 ± 2.43 for ESR group 3 (p for trend \< 0.001). Because CCI was significantly different across the three ESR groups, we added CCI \>= 3 as a new predicting variable in the multivariable analysis for ESR groups (Table 3), prolonged treatment duration (Table 4), and recurrence (Table 5). We have updated all the data in Table 4, 5, 6 and in Supplementary Table 4. The updated ORs were similar to the ORs from the original models. Please see Figure R1 for the comparison. In addition, we re-draw Figure 4, Supplementary Figure 3, 4, and 5 because these figures involve the use of the full models.

 

Figure R1. Results from the original and the updated multivariable models.

\(A\) Original Table 3 vs. Updated Table 3

\(B\) Original Table 4 vs. Updated Table 4

\(C\) Original Table 5 vs. Updated Table 5

Revised content:

1\) Page 11, Line 226: In the RESULTS section under 2nd paragraph, we added one sentence to describe Charlson's comorbidity score: "The mean Charlson's comorbidity index was 1.09 ± 1.69 for Group 1, 1.47 ± 1.91 for Group 2, and 2.04 ± 2.43 for Group 3, which was significantly different (P for trend \< 0.001)."

2\) Page 14, Line 287 & Line 293: In the RESULTS section under the last paragraph, we updated the c-statistic for Model 2-3: "The C statistic of the full model (Model 2-3) indicated moderate-to-good discrimination (0.75; 95% CI, 0.70 to 0.81)". "...their discriminative performance was improved with the addition of clinical information (Model 3-3; C = 0.69; 95% CI, 0.61 to 0.78)..."

3\) Table 1: We added more comorbidities and the Charlson's comorbidity index.

4\) Table 3, 4, 5 & Supplementary Table 4: We added the Charlson's comorbidity in the Model 1-2 and 1-3 (Table 3), Model 2-3 (Table 4), Model 3-3 (Table 5) and Model S1-2 and S1-3 (Supplementary Table 4) and we updated all the data.

5\) Figure 4, Supplementary Figure 3, 4, and 5: We re-draw the ROC curve for prolonged treatment duration (Figure 4) and for recurrence (Supplementary Figure 3). Also, we re-did the two calibration plots for prolonged treatment duration (Supplementary Figure 4) and for recurrence (Supplementary Figure 5).

12\. Were there patients with a simultaneous diagnosis of endocarditis? Was this possibility assessed regularly among patients with infection or bacteraemia documented by gram-positive cocci?

Response: Thank you for this important question. Searching for evidence of infective endocarditis is not a routine at our institution. After carefully screening whether our study population met modified Duke criteria within the 30-day window prior to the diagnosis of PVO, we identified only 3 patients (0.75%) had infective endocarditis (IE). All of them had been treated adequately. In addition, only 1 of these 3 patients were classified in the ESR Group 3 that had high initial ESR and responded slow. Thus, we believe that work-up bias and information bias are unlikely and excluding 3 patients with recent IE would not change our findings.

Revised content: None.

13\. Could it be analyzed if the indication for immediate surgical treatment changed over time? A percentage of 50% seems very high for current practice

Response: We thank the reviewer for this critical concern. In our study, as high as 51% of PVO patients received immediate surgical treatment, possibly due to the high proportion (80%) of patient with abscess that required immediate surgery for local debridement or decompression (Table 1). The indications for surgical intervention for PVO are well-known and they are unlikely to be changed in the past 13 years at our hospital. The proportion of patients receiving immediate surgery or the proportion with abscess did not change much during the study period (Table R5). However, in order to keep a good rapport with patients who have indications of surgical intervention, the decision of operation does not depend solely on in-charge surgeon but also on patients and their family. For regulations of health insurance system and regional cultures of Taiwan, most patients and their family will follow the suggestions of in-charge surgeon.

Table R5. Number of PVO patients who received immediate surgical treatment, by PVO diagnosis year.

Year No. of PVO patients No. of PVO patients with immediate surgery (%) No. of PVO patients with abscess (%)

2002 1 1 (100) 1 (100)

2003 13 5 (38.5) 8 (61.5)

2004 25 15 (60) 20 (80.0)

2005 21 9 (42.9) 17 (81.0)

2006 35 21 (60) 29 (82.9)

2007 31 18 (58.1) 22 (71.0)

2008 36 12 (33.3) 31 (86.1)

2009 40 20 (50) 27 (67.5)

2010 35 17 (48.6) 26 (74.3)

2011 58 35 (60.3) 49 (84.5)

2012 49 20 (40.8) 43 (87.8)

2013 36 24 (66.7) 32 (88.9)

2014 21 9 (42.9) 16 (76.2)

Revised content: None.

14\. The 3 defined trajectory pattern show evident differences in the starting point and evolution of the ESR. However, finally, the prognostic differences seem to be found only between two groups (3 versus 1 + 2 or 1 with respect to 2 + 3 groups). The text and tables 3-5 do not quite clarify this point. In this situation, perhaps after a first descriptive analysis of the 3 groups, the most sophisticated (multivariate) analysis of the outcomes could be done considering the 2 groups that present prognostic differences in the analyzed outcomes; this, in addition, would increase the statistical power to be able to detect differences.

Response: We thank Reviewer for the suggestion. In Table 1 in the main text, the proportion of prolonged treatment was 32%, 59%, and 55.5% for ESR Group 1, 2, 3, respectively. The recurrence was 7.7%, 15.0%, and 19.0% for ESR Group 1, 2, 3, respectively. Since the proportion of prolonged treatment and the proportion of recurrence was comparable for Group 2 and 3, it is reasonable to combine Group 2 and 3 in the multivariable prediction model of ESR group (Table R6). In the full model, initial ESR and ESR-AD remained to be the only two significant predictors for ESR groups, same as the results from the modeling of 3 ESR groups (Table 3).

Table R6. Prediction of erythrocyte sedimentation rate (ESR) trajectory group (Groups 1 vs. 2+3) through logistic regression based on ESR within 4 weeks of pyogenic vertebral osteomyelitis diagnosis.

Variables Crude OR

(95% CI) Model 1-1 (AIC: 252.1) b Model 1-2 (AIC: 238.9) c Model 1-3 (AIC: 240.9) d

　 β Proportional OR

(95% CI) β Proportional OR

(95% CI) β Proportional OR

(95% CI)

Initial ESR, mm/h 1.05 (1.04, 1.06) 0.089 1.09 (1.07, 1.12) 0.090 1.09 (1.07, 1.12) 0.090 1.09 (1.07, 1.12)

ESR -- AD ≥ −9 mm/h a 2.46 (1.56, 3.93) 3.633 37.84 (15.37, 105.48) 3.682 39.72 (14.84, 123.1) 3.679 39.59 (14.76, 122.9)

Age, year 1.02 (1.00, 1.04) 0.002 1.00 (0.97, 1.03) 0.003 1.00 (0.97, 1.03)

Male 0.65 (0.41, 1.03) -0.680 0.51 (0.23, 1.10) -0.683 0.51 (0.23, 1.1)

Diabetes mellitus 3.13 (1.91, 5.27) 0.686 1.99 (0.92, 4.38) 0.683 1.98 (0.92, 4.38)

ESRD 4.78 (1.66, 20.2) 0.424 1.53 (0.24, 12.85) 0.413 1.51 (0.24, 12.85)

Malignancy 2.82 (1.16, 8.43) 1.323 3.75 (0.66, 23.21) 1.318 3.74 (0.66, 23.19)

eGFR, mL/min/1.73 m² 0.98 (0.98, 0.99) -0.010 0.99 (0.97, 1.01) -0.010 0.99 (0.97, 1.01)

CCI ≥ 3 2.77 (1.56, 5.21) -0.224 0.80 (0.28, 2.28) -0.226 0.80 (0.28, 2.27)

Mixed bacteria 2.90 (1.10, 10.0) 0.061 1.08 (0.23, 5.59)

C statistic (95% CI) 0.91 (0.87 - 0.94) 0.92 (0.89 - 0.95) 0.92 (0.89 - 0.95)

Abbreviations: AD, absolute difference; AIC, Akaike Information Criterion; CCI, Charlson's comorbidities index; CI, confidence interval; eGFR, estimated glomerular filtration rate; ESR, erythrocyte sedimentation rate; ESRD, end-stage renal disease; OR, odds ratio; PVO, pyogenic vertebral osteomyelitis.

a\. We used the median value of ESR -- AD as the cutoff value.

b\. In Model 1-1, initial ESR and ESR -- AD were included as predicting variables and the ESR groups (1 vs. 2+3) as the dichotomous response variable.

c\. In Model 1-2, initial ESR, ESR -- AD, demographic information (age, gender), baseline comorbidities (diabetes, ESRD, malignancy, and CCI) and baseline eGFR were included as predicting variables and he ESR groups (1 vs. 2+3) as the dichotomous response variable.

d\. In Model 1-3 (full model), initial ESR, ESR -- AD, demographic information (age, gender), baseline comorbidities (diabetes, ESRD, malignancy, and CCI), baseline eGFR, and polymicrobial infection were included as predicting variables and the ESR groups (1 vs. 2+3) as the dichotomous response variable.

Revised content:

Supplementary Table 4: We added the multivariable prediction model for ESR group 1 vs ESR group 2+3 in the Supplementary Table 4.

15\. In tables 3-5, the different models performed should be explained at the bottom of the table (the tables must be self-explanatory).

Response: Thank you. We have added relevant information to facilitate the readability of these tables. In the top first cell of the first column, we added the column title "Variables" to help readers identify the sequential changes in the adjusted co-variables of all statistical models. In addition, we added footnotes under Table 3, 4, and 5.

Revised content: In Table 3, 4, and 5, we added footnotes to describe the predicting variables and the response variable for each model.

16\. In the multivariate models described in Tables 3-5, how have been decided which variables to include? It seems somewhat arbitrary \... Have all the variables that could influence the prognosis been considered (particularly those kwown variables increasing the risk of recurrence?

Response: Thank you for this important question. These variables were adjusted because they are statistically significant in the univariable analysis (mixed culture, DM, ESRD, malignancy; Table 1) or clinically relevant (CRP, WBC, eGFR). Since poor prognosis is a multifactorial event, we should identify all potential confounders that may be involved in the causal pathway. The best way to illustrate a causal pathway is using a directed acyclic graph or DAG. We provided a DAG for readers to understand the potential confounding induced by the variables we adjusted for (Supplementary Figure 1B; Figure R2).

The main exposure of interest is "4-week ESR variability" and the main outcome of interest is "Poor prognosis" (i.e., prolonged treatment or recurrence). By blocking the backdoor path "4-week ESR variability -- other inflammatory markers -- comorbidities -- age, gender", the independent effect of 4 week-ESR variability on prognosis can be estimated (Figure R2). We addressed this issue in the multivariable analyses (Table 4, 5).

Figure R2. Directed acyclic graph (DAG) for the causal relationship between covariates and poor prognosis among patients with PVO - adjusted for age, gender, comorbidities (i.e., diabetes, ESRD, malignancy, Charlson's Comorbidity Index), other inflammatory marker (i.e., CRP), the presence of abscess, and delayed operation.

Revised content:

1\) Page 9, Line 191: In MATERIALS and METHODS under Statistical analysis, we updated the following sentences: "Furthermore, variables that were statistically significant in the univariable analysis (polymicrobial culture, DM, ESRD, malignancy, CCI; Table 1) or were clinically relevant (CRP, WBC, eGFR) were included in the multivariable analysis. By incorporating the first-4-week ESR variabilities, initial CRP, and other potential confounders, we built several models using logistic regression to predict prolonged PVO treatment (≥ 12 weeks) and recurrence. In addition, we proposed a directed acyclic graph (DAG) to illustrate the potential causal relationship between the first-4-week ESR variabilities and poor prognosis (Supplementary Figure 1)."

2\) Supplementary Figure 1: We added a DAG to illustrate the causal relationship between covariates and poor prognosis.

17\. I suppose that it has been decided to analyze the ESR because it presents a better predictive profile of the evolution of vertebral osteomyelitis. However, I would like to know what the situation in the case of the CRP and why the analysis of this marker was ruled out. In principle, it is thought that CRP could be the parameter of choice. The evolution of leukocytes, CRP and ESR in a single graph could be of interest; it could also be considered to analyze the mentioned markers according to the current 3 defined trajectory patterns. In supplementary figure 1, it is clear that the division into 3 groups of patients in relation to CRP is not useful; in this sense, surgical treatment should probably have an important role that makes interpretation difficult in these patients (in which CRP should have a significant increase in relation to surgery that distorts the overall results); maybe the CRP analysis could be considered excluding surgery patients or excluding CRP increases related to surgery.

Response:

1\) In the initial analysis of GBTM, we did analyze serial measurements of ESR, C-reactive protein (CRP), and white blood cell counts (WBCs) among patients with PVO (Figure 2 and Supplementary Figure 2). Only ESR trajectories distinctly demonstrated different clinical courses among patients with PVO. The CRP level for 79.4% of our study population returned to less than 5 mg/dL in the second week after PVO diagnosis (Group 2, Supplementary Figure 2A). In addition, WBC trajectories did not show significantly different pattern and 73.5% of our study population had flat pattern of WBC (Group 1, Supplementary Figure 2B). Therefore, we focused on ESR as the main marker to predict the disease course of PVO.

2\) To address Reviewer 2's comment, we have plotted the patterns of CRP and WBC throughout the first 6 months of PVO course for each of the current 3 defined ESR groups (Figure R3A). Patients with initial-high ESR (ESR Group 2 and 3) tend to have initial-high CRP as well. However, the CRP declined consistently across three ESR groups with similar magnitude during the first 1-2 weeks and after that. The correlation between ESR and CRP then disappeared after the fourth month of treatment. As for WBC pattern (Figure R3B), there's no distinct difference across the 3 ESR groups since the second month of treatment. Therefore, in treating patients with PVO, ESR would be a superior follow-up marker with a noticeable resolution in guiding treatment courses.

Figure R3. The pattern of C-reactive protein (CRP) and the pattern of white blood cell count (WBC) within the first 6 months of PVO diagnosis, stratified by the three ESR trajectory groups.

\(A\) CRP pattern by ESR group

\(B\) WBC pattern by ESR group

3\) We agree with Reviewer 2 that surgery per se may interfere the level of CRP. For instance, in an early study done by Larsson et al., they examined the CRP levels after elective orthopedic surgery and found that the CRP increased and peaked on the second or the third day after the surgery, followed by dropping to normal within 21 days postoperatively \[8\]. However, this finding may not extrapolate to surgical intervention for infectious diseases. In our study, the initial level of CRP was the highest for patients receiving operation (either immediate or delayed) and the CRP remained higher for patients with delayed operation within the first 4 weeks (Figure R4). However, the CRP level decreased to similar level for all patients within 5 weeks after the PVO diagnosis, regardless of their operation status. Therefore, this phenomenon indirectly supports the use of ESR in predicting the clinical course of PVO. We think that excluding patients undergone surgery while analyzing the CRP patterns would not be appropriate because 271 patients (67.6%) in our study population would be excluded.

Figure R4. The pattern of C-reactive protein (CRP) within the first 6 months of PVO diagnosis, stratified by the surgical treatment.

Revised content:

1\) Page 15, Line 304: In the DISCUSSION section under the first paragraph, we added: "Additionally, WBC trajectories did not show significantly different pattern and 73.5% of our study population had flat pattern of WBC (Group 1, Supplementary Figure 2B). "

2\) Page 15, Line 316: In the DISCUSSION section under the first paragraph, we added: "In fact, the CRP level for 79.4% of our study population returned to less than 5 mg/dL in the second week after PVO diagnosis (Group 2, Supplementary Figure 2A)."

18\. Figure 3 is not very intuitive

Response: We agree with the reviewer that this probability graph is not intuitive for most clinicians; however, we humbly ask to keep this graph for readers who are interested in applying the findings of medical research in real practice. First, we have provided case studies in the plot to illustrate how to interpret this probability graph. Second, in the era of electronic medical records (EMRs), it is easy to embed this probability graph into EMR system. We have specifically highlighted (black-dashed line) the two hypothetical patients in the revised Figure 3 to improve its readability.

Revised content:

Figure 3: We have specifically highlighted (black-dashed line) the two hypothetical patients in the figure to improve its readability.

Discussion

19\. Lines 275: "The inflammatory marker CRP returns to its normal level within 1 week". Maybe it means \"may\" (or something similar) returns?

Response: Thank you. We have toned down the expression and modified this sentence accordingly.

Revised content:

Page 15, Line 312: We have edited the following sentence: "The inflammatory marker CRP may return to its normal level within 1 week."
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